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Replacing of animal by plant protein in foods is currently an important topic of 
discussion due to the ecological and physiological benefits associated with 
vegetable sources of proteins. In view of the growing global population, as well 
as, the limited availability of agricultural lands, there is an urgent need for high 
quality proteins from sustainable plant sources such as legumes (e.g., soy, pea, and 
lupin). Animal proteins are expensive in terms of market price, land requirement 
and environmental impact, on the other hand, vegetarian sources of protein are 
almost always incomplete proteins not getting all nine essential amino acids from 
foods. However is established as eating a variety of vegetable source proteins one 
can obtain the complete range of amino acids and the recommended daily protein 
requirement. Vegetable proteins also supply essential fats, complex carbohydrates, 
and fibers. Ultimately vegetable proteins are economic and versatile alternative to 
animal proteins as functional ingredients in food formulations and among plant 
proteins, legumes represent, together with cereals, the main plant source of 
proteins in human diet. 
 
     1.1 Legumes Proteins 
1.1.1 Nutritional importance of legumes 
Legumes have played a vital part in many ancient civilizations. The use of legumes 
as a basic dietary staple can be traced back more than 20,000 years in some eastern 
cultures. Legumes are crop plants from the family Fabaceae (or Leguminosae). 
The key characteristic of legume plants is the ability, of nearly all its members, to 
fix atmospheric nitrogen to produce their own protein compounds thanks to the 
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symbiotic association with nitrogen‐fixing bacteria (i.e. rhizobia) found in the root 
nodules. 
Leguminous seeds are an important source of food proteins. The beneficial effect 
of dietary intake of legume seed are the basis of various health claims. Grain 
legumes are widely recognized as important sources of food and feed proteins. In 
many regions of the world, legume seeds are the unique supply of protein in the 
diet and very often they represent a necessary supplement to other protein sources. 
On the other hand in developed countries plant proteins can now be regarded as 
versatile functional ingredients or as biologically active components more than as 
essential nutrients. This evolution towards health and functionality is mainly 
driven by the demands of consumers and health professionals, such as the partial 
replacement of animal foods with legumes is claimed to improve overall 
nutritional status and, the needs of the food industry, respectively (Duranti M., 
1997). Legume seeds accumulate large amounts of proteins during their 
development. They are stored in membrane bound organelles (protein bodies) in 
the cotyledonary parenchyma cells, survive desiccation on seed maturation and 
undergo hydrolysis at germination, thus providing ammonia and carbon skeletons 
to the developing seedlings. Seed proteins that behave in this way are termed 
'storage proteins'. However, because of their insolubility in water and solubility in 
salt solutions, the storage proteins are also named globulins and the two terms are 
commonly used interchangeably. Besides storage proteins, legume seeds contain 
several comparatively minor proteins including trypsin inhibitors, lectins, 
lipoxygenase and urease, which are relevant to the nutritional quality of the seed. 
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Some of them, like urease from jack-bean, also seem to have adopted a storage 
role by virtue of their amount in the seed (Casey R., 1986). 
 
1.1.2  Nutritional value of legume seed proteins 
1.1.2.1 Nutritional Value  
All legume seed proteins are relatively low in sulphur-containing amino acids and 
tryptophan, but the amounts of another essential amino acid, lysine, are much 
greater than in cereal grains (Ampe et al., 1986; Rockland L.B., 1981). Therefore, 
with respect to lysine and sulphur amino acid contents, cereal and legume proteins 
are nutritionally complementary. The degree of mutual supplementation may also 
depend, however, on the contents of second limiting amino acids, i.e. threonine in 
cereals and tryptophan in legumes (Duranti M., 1997).  
Lupin flours can be an excellent choice for improving the nutritional value of food 
products. The high lysine, low methionine content complements that of wheat flour 
proteins, which are poor in lysine and relatively higher in the sulphur-containing 
amino acids. In lupins, the main limiting amino acids are methionine and cystine, 
followed by valine and then tryptophan. Since lupins are legumes, the lack of 
sulphur-containing amino acids is not surprising, valine seems to be adequate in 
L. albus (Aguilera J. M., 1978). Lupin protein isolates, prepared on a bench scale, 
have been shown to have good nutritional properties when supplemented with 
methionine or mixed with cereals (Ruiz, 1976). Studies have shown that lupin flour 
can be successfully incorporated into products at up to 20% inclusion, to produce 
products that rate higher in terms of color, texture, taste and overall acceptability 
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than the control (Kohajdová Z. ;Karovičová, 2011). A number of pasta products 
containing lupin flour are currently available on the domestic market (Kyle, 1994). 
Soybean flours are increasingly being used in many countries because they are a 
good source of vegetable proteins, with a low fat content. The nutritional value of 
the soybean is not the only factor enhancing its consumption, as it plays an 
important role in health (Jacques et al., 1992a, b). All nine of the essential amino 
acids required by humans can be found in the amino acid composition of soybean. 
A digestibility of 95–100% has been found in isolated soybean protein in 
evaluations of animals and humans (Jacques et al., 1992b). Moreover, the essential 
amino acid content in soybean exceeds the amino acid requirements of children 
and adults, which confirms the protein quality of this vegetable.  
 
1.1.2.2 Legume seed antinutritional compounds 
Legume seeds contain several antinutritional protein and non-protein compounds. 
The presence of anti-nutritional compounds in crop plants is the result of an 
evolutionary adaptation which enables the plant to survive and complete its life 
cycle under natural conditions, regardless of the negative consequences on the 
quality and safety of the food products. Indeed, due to their anti-nutritional or even 
toxic properties, various potentially harmful compounds have been shown to play 
a protective role against insects, fungi, predators and a number of stress conditions 
(Peumans and Vandamme, 1995).  
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1.1.2.3 Protein antinutritional compounds 
To this class belong seed hydrolase inhibitors, which are important in determining 
the quality of legume seeds.  Their antinutritional effect in the irreversible 
inhibition of various digestive enzyme is well documented (Leterme et al., 1992). 
If inactivate, the protein inhibitors may even play a positive nutritional role, due 
to their high content of sulfphur-containing amino acids relative to the majority of 
the seed proteins. The most important protein inhibitors are Trypsin Inhibitors 
(Tis) of both the Bowman-Birk type in Pisum sativum and Kunitz type in Glicine 
max and -amylase inhibitors. It has been shown that the Tis, have been proven to 
act as protective agents against insect attack (Hilder et al., 1990; Johnson et al., 
1989; Liener, 1986; Moreno et al., 1990). Seed lectins are sugar-binding proteins, 
as well as hemagglutinins, which are able to agglutinate red blood cells. Some 
lectins can cause agglutination of the red blood cells followed by hemolysis and, 
in extreme cases, death. Allergies to legume seeds are relatively uncommon in 
humans due to the low allergenic capacity of storage proteins (Lallès, 1996), but 
they could develop with increased consumption.  
 
1.1.2.4 Non-Protein antinutritional compounds 
Legume seeds contain a number of non-protein antinutritional compounds with 
significantly different structures and effects. To this class belong: alkaloids, phytic 
acid, phenolic compounds, saponins, vicine and convicine. Alkaloids limit the 
acceptance of various legume seeds, such as lupin, both for their strong bitter taste 
and toxicity (Cuadrado, 1992). Due to the water solubility of alkaloids and their 
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low size, it is possible to remove them from the seeds by soaking and cooking in 
water. A probable role of alkaloids can also be to provide the seeds pest protection. 
In addition, alkaloids extracted from lupin seeds can be used for pharmacological 
and other biomedical purposes. Phytic acid, is present in legume seeds, making up 
the major portion of the total phosphorous in the seed. Phytic acid is responsible 
for the reduction of the bioavailability of essential minerals, forming insoluble 
complexes which are less available for digestion and absorption in the small 
intestine. Phenolic compounds, such as tannins, can crosslink with proteins by 
reacting with lysine or methionine residues, making them unavailable during 
digestion (Davis, 1981). Vicine and convicine are confined to Vicia and are known 
to be responsible for a type of hemolytic anemia, known as favism. Legumes are 
well known inducers of intestinal gasses (flatulence), due to the presence of -D-
galactopyranosyl residues bound to the glucose moiety of sucrose. Animals and 
humans are not able to digest such oligosaccharides, because of the absence of -
galactosidase in their intestinal mucose, consequently the galactosides pass into 
the colon and are fermented by the intestinal bacteria with production of gas 
(Fleming, 1981). Saponins are a diverse group of compounds commonly found in 
legumes; their general structure consists of a steroid or triterpene group linked to 
one or more sugar molecules. The presences of both polar and non-polar groups 
provide saponins with strong surface-active properties, which are responsible for 
their adverse biological effects. A well-known toxic effect of saponins is their 
ability to lyse erythrocytes, as well as other cells, such as those found in the 
intestinal mucose, thus affecting nutrient absorption. 
17 
 
1.2 The seed proteins 
Legume seeds accumulate large amounts of proteins during their development. 
Despite wide variation in their detailed structures, all seed storage proteins have a 
number of common properties. First, they are synthesized at high levels in specific 
tissues and at certain stages of development, in fact, their synthesis is regulated by 
nutrition, and they act as a sink for surplus nitrogen. However, most also contain 
cysteine and methionine, and adequate sulfur is therefore also required for their 
synthesis. Many seeds contain separate groups of storage proteins, some of which 
are rich in sulfur amino acids and others of which are poor in them. The presence 
of these groups may allow the plant to maintain high levels of storage protein 
synthesis despite variations in sulfur availability. Storage proteins are stored in 
membrane bound organelles (protein bodies) in the cotyledonary parenchyma 
cells, survive desiccation on seed maturation and undergo hydrolysis at 
germination, thus providing ammonia and carbon skeletons to the developing 
seedlings. Osborne (1924) classified them into groups on the basis of their 
extraction and solubility in water (albumins), dilute saline (globulins), alcohol-
ether mixtures (prolamins), and dilute acid or alkali (glutelins). The major seed 
storage proteins include albumins, globulins, and prolamins. 
 
1.2.1 Classification of seed storage proteins 
Legume seeds accumulate proteins during their development, most are bereft of 
catalytic activity and play no structural role in the cotyledonary tissue. For the 
18 
 
insolubility in water and solubility in salt solutions, the storage proteins are also 
called globulins. 
 
1.2.2 The globulins  
The globulins are the most widely distributed group of storage proteins; they are 
present not only in dicots but also in monocots (including cereals and palms) and 
fern spores. They can be divided into two groups based on their sedimentation 
coefficients (SV20): the 7S vicilin-type globulins and the 11S legumin-type 
globulins. Both groups show considerable variation in their structures, which result 
partly from post-translational processing. In addition, both are deficient in cysteine 
and methionine, although 11S globulins generally contain slightly higher levels of 
these amino acids.  
 
1.2.3 The 11S globulins 
The 11S legumins are the major storage proteins not only in most legumes but also 
in many other dicots and some cereals (oats and rice). The mature proteins consist 
of six subunit pairs that interact with non covalent bond. Each of these subunit 
pairs consists in turn of an acidic subunit of MW, ~40,000 Da and a basic subunit 
of MW, ~20,000 Da, linked by a single disulfide bond. Each subunits pair is 
synthesized as a precursor protein that is proteolytically cleaved after disulfide 
bond formation. Legumins are not usually glycosylated, an exception being the 
12S globulin of lupin (Duranti, 1988). 
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1.2.4 The 7S globulins 
7S globulins are typically trimeric proteins of MW, ~150,000 to 190,000 Da that 
lack cysteine residues and hence cannot form disulfide bonds. Their detailed 
subunit compositions vary considerably, mainly because of differences in the 
extent of post-translational processing (proteolysis and glycosylation). For 
example, the vicilin subunits of pea are initially synthesized as groups of 
polypeptides of MW, ~47,000 and ~50,000 Da, but post-translational proteolysis 
and glycosylation then give rise to subunits with MW values between 12,500 and 
33,000 Da. These subunits are difficult to purify and characterize, but molecular 
cloning allowed their origins and the sites of proteolytic cleavage and 
glycosylation to be identified. The globulins of soybean and common bean are 
extensively  glycosylated, while in pea and the fava bean virtually no glycosylation 
occurs, but processing by proteolytic cleavage is common (Shewry P.R.; Napier, 
1995). 
 
1.3 Functional food: soybean and lupin proteins for hyperlipidemia and 
glucose control   
1.3.1 Functional foods 
A close relationship exists between diet and major diseases of the industrialized 
world such as hyperlipidemia, obesity, diabetes, metabolic syndrome, and tumor 
development.  
However, the only dietary intervention or, alternatively, the use of specific drugs 
may not be sufficient to prevent and treat these diseases, because there may be 
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contraindications to their use. Therefore, is necessary to identify innovative 
approaches for their prevention and treatment involving the use of compounds 
effective but non-toxic, and possibly present in the foods themselves. 
The functional foods are a large and heterogeneous group of food products, which 
are characterized by having specific beneficial properties. In fact, although there 
is still no universally accepted definition for the term "functional food", there is a 
general consensus that functional foods are special foods that can confer specific 
health effects to the diet beyond the simple nutrition value. It is extremely 
important to emphasize that the fundamental characteristic of a functional food is 
just in his nature to be a food and not a product in the form of pills, tablets or 
capsules. The market for functional foods, although still " niche" has increased 
rapidly over the past few years. The reasons for the growth of the market for 
functional foods lies in the increased awareness of the role of diet in maintaining 
a level of optimum health and prevention of specific diseases related to sedentary 
lifestyle and unbalanced diet (obesity, hypertension, osteoporosis, diabetes, 
cardiovascular diseases, etc.).  
How easily derived, is rather difficult to establish a precise and universal definition 
of the term “functional food” given the large and diverse group of food products 
to which it refers. In other words, we cannot yet have an official definition, 
common to all states that produce and trade for functional foods.  
Today we have experimental evidence that peptides from soybean and lupin can 
play function of nutraceutical compounds able to reduce plasma cholesterol, 
triglycerides and glucose concentrations. However, the molecular determinants 
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responsible for these activities and their mechanism/s of action are actually under 
study. 
 
1.3.2 Biological activity of legume proteins and their impact on the 
nutraceutical and supplements industry  
The business for nutraceutical ingredients in the world is worth € 50 billion and 
continues to grow (source Cordis - Information Service of the European 
Commission in the field of research and development for science). Currently the 
leader in the industry are the United States and Japan, with an ever-increasing 
progress of EU countries (eg; France). In this business field numerous products 
with hypocholesterolemic action (for example, products based on phytosterols) are 
present which base their mechanism of action on preventing the absorption of 
dietary cholesterol and the reabsorption of endogenous cholesterol in the 
gastrointestinal tract.  The molecules that are discussed in this regard instead with 
their innovative mechanism of action (after confirmation following on human 
beings test), will be open to the sector of prevention, generating a strong impact 
on businesses as well as the health of the consumer. 
 
1.3.3 Consumer Health care: cost, risk prevention and drug consumption  
The diseases that have the greatest impact on the healthcare and pharmaceutical 
industries are: metabolic syndrome, coronary heart disease and tumors. 
In the coming years, health care spending is set to increase, since there is a higher 
risk of developing cardiovascular disease. Dyslipidemia is an important 
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cardiovascular risk factor which can be modified through targeted actions for its 
prevention.   
The cardiovascular system drugs are the drugs most commonly used (32.7%) with 
a coverage of 94% of the Italian health system (SSN), although there are regional 
variations. The National Report 2007 shows the expenditure per capita in 
Lombardia amounted to EUR 197.5. 
Functional foods may be defined differently in function of the context in which 
they are considered: the public, the food industry or agriculture. The most 
commonly accepted definition is the one that treats them as “products formulated 
with natural chemical components with the function to provide health benefits, 
lowering the risk of some diseases, participate in specific biological processes or 
correct some diseases caused by nutritional deficiencies”. Nutritional foods are 
often referred to as nutraceuticals. Some of them are similar to conventional foods, 
are used as components of a usual diet and are able to produce health benefits 
and/or reduction of chronic diseases. Others are obtained from the same foods but 
are marketed as dietary or medicinal formulations; they are also able to exercise 
beneficial physiological activity or protective activity against chronic diseases 
(Stephen, 1998).  
Functional foods may be obtained in different ways, and today, the techniques used 
in this field are constantly changing. The most common modifications are designed 
to the production processes of the food which allow more retention of some 
components that would otherwise be lost, selection of plants which enable for 
obtaining of new cultivars with modified composition of the food product. 
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Application of genetic interventions that allow to obtain foods with characteristics, 
sometimes very specific depending on the requirements is the general 
improvement of the techniques of industrial production. 
The beneficial effect of functional foods may be determined by the presence of 
components characterized by varied chemical nature including alkaloids, saponins, 
isoflavonoids, phytates and proteins of various nature. In the latter case, the 
biological activity may be due to peptides released from food proteins after 
enzymatic digestion. The hydrolysis can take place during the process of 
gastrointestinal digestion or result from processes of germination, fermentation 
(the proteolytic system of bacteria is able to contribute to the liberation of peptides) 
and food handling. 
 
1.4 Soy protein  
Evidence of the beneficial properties of legume seed proteins in the prevention and 
even therapy of various diseases, many of which typical of the affluent countries, 
is currently accumulating. In particular, pathologies such as diabetes, cancer, 
cardiovascular disease (CVD), hypertension and obesity appear to be involved. A 
health claim related to legume seed protein dietary intake as a mean to prevent 
heart attack and other CVD-related syndromes has already been published. More 
recently, other scientists' boards have claimed that "grain legumes effectively 
contribute to a balanced diet and can prevent widely diffused diseases, including 
type II diabetes and cardiovascular diseases" (Alissa, 2011) 
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Soybean storage proteins have already been shown to play a major role in the 
plasma lipid homeostasis control. This biological activity was the basis of a USA-
Food and Drug Administration (USA-FDA) health claim in 1999. In particular, 
soy proteins have been defined by the USA-FDA as a powerful tool in reducing 
the risk of cardiovascular disease. A daily intake of 25 gr of soy protein may reduce 
the value of LDL cholesterol by  10-20% of in hypercholesterolemic patients 
(FDA, 1999) 
 
 
 
 
 
 
 
 
 
Fig.1 Glycine max (soy) 
 
1.4.1 Classification  
The components present in greater quantities in soy are proteins, which on average 
constitute up to 40% of the total dry substance (Liu, 1997) .  
Storage globulins comprise two main protein constituents in soybean seeds that 
can be differentiated by their sedimentation coefficients, the 7S protein or -
conglycinin and the 11S protein or glycinin. The 11S fraction is a non-glycosylated 
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protein characterized by 12 polypeptide chains divided into 6 basic and 6 acid 
subunits with an overall molecular weight around 350,000 Da. The fraction 7S, 
molecular weight around 150,000 Da, is a glycoprotein formed by three different 
subunits, α, α' and β, associated in various combinations. Within the protein, α, α' 
and β are present in ratio 2:1.7:1 and have molecular weights of 67, 71 and 50 kDa 
respectively. Taking advantage of the different isoelectric point its possible 
separate the two globulins. 
 
1.4.2-Conglycinin 
1.4.2.1 Different purified fractions of -conglycinin           
The proteins of the soybeans are represented by two major components, glycinin 
and - conglycinin, which amounted to 40 % and 30 % compared to total protein 
(Utsumi, 1997a). In the literature there are references about 
conglycinin. These terms were defined by Catsimpoolas and Ekenstam 
(1969), referring to the three distinctive separated cractions from a crude 
preparation of conglycinin. Following further studies Catsimpoolas states that in 
-conglycinin has enzymatic activity typical of the 2S subunit. - and -
Conglycinin not have enzymatic activity and differ from the other according to the 
ability to polymerize reversibly at neutral pH following a decreasing ionic strength 
from 0.5 to 0.1 M. -conglycinin has a coefficient of sedimentation of about 7S at 
high values of ionic strength and 9-10 S for smaller values of ionic strength; this 
property is not found for -conglycinin . Because of its high proportion in the 7S 
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fraction, -conglycinin was studied more intensely than - and -conglycinin (Liu, 
1997). 
 
1.4.2.2 The composition of -conglycinin subunit 
-conglycinin has a trimeric structure analogous to that of other 7S globulins 
(Utsumi, 1997a) and is composed of three kinds of subunit namely , ' and .  
The  and ’ subunit of -conglycinin are composed of the extension regions (, 
125 residues, ’, 141 residues) and by “core” region (418 residues for the  and 
’) (Maruyama et al., 1998). subunit consists only of the “core” region (416 
residues), as presented in the Figure 2. All subunits are glycosylated (Utsumi, 
1997b). 
 
 
 
 
 
 
 
 
 
 
 
 
        Fig.2  
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Fig.2: The amino acid sequences of the ' and  subunits are shown by dots (.) when they 
are identical to those of the  subunit and by letters when non-identical. Dashes (-) are 
introduced for maximal alignment of the sequences. Arrowhead indicates the position 
where the insert sequence reported by Doyle et al. occurred. The regions corresponding 
to the deletion mutants c (position 126-543 of  subunit) and 'c (position 142-559 of 
’subunit) are surrounded by a box. 
 
1.4.2.3 Different molecular species of -conglycinin 
In the presence of denaturing agents such as urea and SDS, the proteins of 
leguminous 11S and 7S release their constituent polypeptide chains (Duranti M., 
1997) that can be solved using a ion exchange chromatography (Liu, 1997). 
These polypeptides are naturally heterogeneous, (Pusztai and Stewart, 1980) the 
heterogeneity is evident both in size and in the charge levels (Brown et al., 1981; 
Horstmann et al., 1993; Tucci et al., 1991) and resulting from a combination of 
two factors, the multi gene origin of each globulin and post-translational 
modifications (Wright, 1986). The relative contribution of these factors varies 
significantly between different genes and inside of the same genus. (Duranti M., 
1997). It is evident that the mechanisms for the assembly of the native proteins 7S 
and 11S from their heterogeneous subunits are not clearly defined that the random 
association can occur in many cases (Gatehouse et al., 1981),  this exponentially 
increases the number of molecular species in both classes. The situation is further 
complicated by the fact that many of these proteins, especially the 7S, are 
glycosylated in irregular way (Duranti M., 1997). Among the ten species of -
conglycinin theoretically possible, six (from B1 to B6) were isolated (Thanh, 1976) 
(Table 1). 
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Table 1. Compositions in the subunits of the six molecular species of conglycinin 
 
The six form of -conglycinin are able to dimerize in a reversible manner to low 
levels of ionic force or to a pH between 4.8 and 11.0. 
 
1.4.2.4 Structure-function relationships at the molecular level: the properties 
of -conglycinin  
The functional properties of the three subunits , ', and , of conglycinin have 
been described using recombinant proteins obtained by means of an expression 
system with E. coli. (Maruyama et al., 1999). The use of recombinant proteins is 
necessary for the presence of different molecular species of conglycinin in the 
seeds of Glycine max. The expression systems used by Utsumi and Maruyama 
have provided homogeneous molecular species of conglycinin and  and ' 
subunits without regions of the extension. 
Solubility: The properties of gelation and the formation of foams and emulsions, 
are based on the solubility of the conglycinin in the solution medium. 
conglycinin soluble in water but not in saline solutions (Osborne, 1924). The 
isoelectric point of conglycinin is between 4.8 and 4 (Koshiyama, 1968) . Like 
the native protein, at a value of ionic strength equal to 0.5 M, the  and '  
B1 1' and 2 
B2 1 and 2 
B3 1 1' and 1 
B4 2 and 1 
B5 21' 
B6 2 
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recombinant subunits are soluble. To a value of 0.08 M ionic strength the two 
recombinants subunits are insoluble at pH value greater than 4.8. While the native 
protein is insoluble in a more restricted range of pH. It is evident that the 
oligosaccharide residues of the native protein and the of extension regions of the 
 and ' subunit will greatly affect the solubility. 
Thermal stability: At pH 7.6 and 0.5 ionic strength of the thermal stability of the 
individual subunits , ' and  are equal to 90.8 °C, 81.7 °C and 78.6 °C 
respectively. Under equal conditions, to the regions of the "core" of  and 'values 
are equal to 77.3 °C and 83.3 °C respectively (Maruyama et al., 1998); for the -
conglycinin native will have two different values, 79.0 °C and 83.1°C. These 
experimental results suggest that the oligosaccharide residues do not contribute to 
thermal stability of the native protein and that, the stability of the different 
molecular species is conferred by the subunit having the lower denaturation 
temperature between the subunits constituting the protein. 
 
1.4.3 The cholesterol-lowering activity of -conglycinin 
The hypocholesterolemic property of purified proteins from soy has been clearly 
demonstrated in animal models and in humans (Carroll, 1991). The reduction of 
serum cholesterol is apparently associated with the activation of the receptors for 
the catabolism of the major transporters of cholesterol in plasma, the low density 
lipoproteins (Lovati et al., 1987; Sirtori et al., 1997). In this regard two hypotheses 
have been proposed; a direct effect of the protein (mainly 7S and 11S globulins or 
fragments thereof), or an effect of soy isoflavones: daidzein and geneistein. Both 
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of these assumptions are based on experimental findings and clinical outcomes 
(Anderson et al., 1995; Erdman, 1995). 
 
1.4.3.1 Increased expression of the LDL receptor-cholesterol by -conglycinin 
The exposure of 7S soy globulin in HepG2 cells at different concentrations was 
associated with a dose-dependent increase in the uptake and degradation of LDL 
cholesterol (Lovati et al., 1992; Lovati et al., 1996). Further evidence showed that 
the expression of LDL receptors on blood type system cells, lymphocytes, 
increases following the consumption of soy protein (Lovati et al., 1987). 
Subsequently, the metabolic fate of the individual subunits of -conglycinin was 
studied in HepG2 cells. In the first place it has been demonstrated that the 7S 
globulin interacts at the cellular level with the binding sites sensitive to heparin-
sensitive binding sites with little competition from the more abundant proteins 
present in the incubation medium. A study based on laser fluorescence showed that 
the globulin 7S is picked up by HepG2 and subjected to proteolysis only in the 
extra-nuclear compartment(Manzoni et al., 2003). It was also observed that in 
HepG2 cells, after 96 hour exposure to 7S soy globulin the the  and ’subunits 
were not in their original primary structure while the  subunit resulted essentially 
indigested. Finally, while subunit did not increase the expression of LDL 
receptor,  and ’ subunits showed powerful LDL receptor induction (Lovati, 
1998). In the system used to evaluate the cholesterol-lowering property of -
conglycinin, the soy isoflavones contenent was present in very low concentrations. 
In order to confirm that the LDL receptor activity of soy may reside in the protein 
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we explored, in the same experimental system, the LDL receptor of proteins 
isolated from a commercial isoflavones-free soy protein concentrate (Croksoy). 
Previous studies from our group had indicated indirectly, between the subunits 
constituting the 7S globulin (, ' and ) that the ' subunit as likely responsible 
for increased LDL receptor activity. This hypothesis was formulated on the basis 
of the very clear lack of LDL receptor activation by a mutant soybean variety 
“Kebury” lacking the ’ subunit of -conglicinin. These conclusions have been 
confirmed directly thanks to the availability of purificated ’subunit separated 
from 7S globulin by affinity chromatography on a matrix containing Zn2+. This 
technique was adopted starting from the observation that the ' contains, in the 
region of extension, a number of histidines higher than that of the  subunit which 
are able to bind several transition metals, including  Zn2+. The exposure of HepG2 
cells in the condition previously described, to purified, ' subunit has determined 
the activation of LDL receptor and, in parallel the increase of LDL receptor 
promoter activity (Manzoni et al., 2003).  
This confirms that the LDL receptor activating-cholesterol lowering properties of 
soy proteins, was due to the ' subunit of the 7S soy. These results suggest that the 
activation properties of the receptors for LDL cholesterol can be traced to a stretch 
of 37 amino acids that are found in the N-terminal region of the subunit ', but not 
subunit (Wright, 1998). An additional hypotheses about the activity of ' lies in 
the possibility of an interaction with sterol regulatory element protein, such as 
SREBP-2, able to increase the expression of the LDL receptors (Manzoni et al., 
2003). 
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1.4.3.2 Interaction of -conglycinin with thiredoxin 1 (Trx1) and cyclophilin 
B (CyPB) 
The interaction of the 7S globulin with cell membranes occurs through specific 
binding with proteins from the relatively low molecular weight (Lovati et al., 
1996). Analysis of the N-terminal amino acid sequence of the proteins involved in 
these interactions have identified two specific protein ligands: Trx 1 and CYPB 
(Manzoni et al., 2003). The fundamental role of these two proteins in cellular 
homeostasis is widely recognized and confirmed by their relevant conservation 
during evolution (Arner and Holmgren, 2000). Cyclophilin B, belonging to the 
family of peptidyl-proline cis-trans isomerase (Bergsma et al., 1991), is a 
cyclosporine binding-protein (Cacalano et al., 1992); is primarily associated to the 
cell secretory pathway and is essential for the folding structure of proteins in vivo 
(Hoffmann and Schiene-Fischer, 2014; Steinmann et al., 1991) 
In particular, CyPB is stored both in the endoplasmic reticulum both in complexes 
on the plasma membrane (Allain et al., 1994). Thioredoxin 1 is a small 
multifunctional protein, with a complex redox in the conserved sequence of the 
active site (-Cys-Gly-Pro-Cys) (Lillig and Holmgren, 2007) that plays a variety of 
roles from elimination of the reactive species of oxygen to the regulation of the 
proliferation of some cell types. It has been observed an increase of the expression 
of Trx and glutaredoxin 1 in samples of human coronary arteries as a result of 
intake of soy protein; this suggests a possible involvement of dithiol-disulfide 
oxidoreductase complex in the protection of human coronary (Okuda et al., 2001). 
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The involvement of these proteins main help to understand the complex 
mechanisms involved in reducing the progression of the atheromatous plaques 
observed after administration of a diet with soy proteins in an animal model of 
human soft plaques (Castiglioni et al., 2003) 
Has been observed “in vitro”  interaction of 7S globulin with Trx 1, this suggests 
that Trx 1 could to act as a carrier of the 7 S globulin in the cells, where it acts by 
regulating the expression of the receptors for LDL cholesterol (Manzoni et al., 
2003). The interaction of 7S globulin with CyPB, however, suggests the 
involvement of this vegetable protein in the cholesterol transport between the 
endoplasmic reticulum and the cavity of the cell surface of the arteries.  
 
1.5 Cholesterol and Atherosclerosis 
1.5.1 The functions of cholesterol in the human body 
Cholesterol is the typical sterol of animal cells. In vertebrates, the most amount of 
cholesterol is produced in the liver. A small part of cholesterol is incorporated into 
the membranes of the hepatocyte, while a large portion is exported under one of 
the two possible forms: bile acids or cholesterol esters. Bile acids and their salts 
are relatively hydrophilic derivatives of cholesterol synthesized in the liver to 
promote the digestion of lipids. Cholesterol esters are formed in the liver by the 
action of cholesterol acyl transferase. This enzyme catalyzes the transfer of a fatty 
acid from acetyl coenzyme A to the hydroxyl group of cholesterol, converting the 
cholesterol in a form even more hydrophobic. Cholesterol esters are stored in the 
liver or are transported in those tissues that use cholesterol. 
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All animal tissues during growth need cholesterol for the synthesis of membranes 
and some organ (for example, the adrenal cortex and the gonads) since it is used 
as precursor for the production of steroid hormones. Cholesterol is also the 
precursor of vitamin D. (Cox, 1993). 
 
1.5.2 The transport of cholesterol 
Cholesterol esters that must be transported to peripheral tissues, are secreted into 
the blood as constituents of lipoprotein complexes called very low density 
lipoproteins (VLDL). 
During the movement of VLDL, triglycerides, and most of their apolipoprotein are 
removed in the capillaries of muscle and adipose tissue, converting sequentially 
VLDL into intermediate density lipoproteins (IDL), and then in low density 
lipoprotein (LDL). The peripheral tissues, normally, derive the majority of their 
exogenous cholesterol from LDL by receptor-mediated endocytosis. Inside the 
cell, cholesterol esters are hydrolyzed by a lysosomal lipase in free cholesterol, 
used by cells or which is esterified by acyl transferase cholesterol to be stored as 
droplets of esters from cholesterol. Cholesterol, cholesterol esters and triglycerides 
from food are transported in the blood by lipoprotein complexes synthesized in the 
intestine and are called chylomicrons. After removal of triglycerides from the 
peripheral tissues, chylomicrons residues bind to specific receptors of the liver 
cells and are internalized via receptor-mediated endocytosis in a manner similar to 
that of LDL. In the liver, the dietary cholesterol is used in the biosynthesis of bile 
acids or compacted into VLDL to be excreted. Cholesterol circulates constantly in 
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the blood, between the liver and the peripheral tissues. While LDL transport 
cholesterol from the liver, cholesterol is transported back to the liver by the high 
density lipoproteins (HDL) (Voet, 1992).When the amount of cholesterol 
synthesized and obtained from the diet exceeds the amount necessary for the 
synthesis of cells membranes, bile salts and sterols, the pathological accumulation 
of cholesterol in the blood vessels can lead to the formation of atherosclerotic 
plaques capable to obstruct the vessels. The atherosclerosis is related to high levels 
of cholesterol in the blood and in particular to the levels of cholesterol bound to 
LDL; there is in fact, an indirect correlation between HDL levels and coronary 
damage (Cox, 1993).  
According to the National Institute of Health deaths caused by atherosclerosis in 
Italy in 2008 amounted to 6808; 64% of these deaths belong to the female 
population. Cardiovascular diseases (CHD), the deadline of a slow process of 
atherosclerosis of the blood vessels are the leading cause of death in Western 
countries, especially the United States of America and northern Europe. Many 
factors contribute to their development, and between them a fundamental role is 
played by the recruitment of a diet rich in animal fats and low in protein of plant 
origin. It should be remembered that only 5% of the population atherosclerosis is 
genetic origin, while in the remaining 95% is related to etiology of eating habits 
and behavior of individuals, which are crucial in particular for plasma cholesterol 
levels. The increase in plasma lipids, particularly cholesterol and low density 
lipoproteins (LDL), is one of the key factors in the onset and development of 
atherosclerosis. Numerous studies conducted both in animal models and humans, 
36 
 
have shown how this increase is caused not only by the presence in the diet of 
cholesterol and saturated fatty acids, but also by proteins of animal origin.  
 
1.5.3 The LDL receptor 
The LDL-R gene provides instructions for making a protein called a low density 
lipoprotein receptor (Kong et al., 2006). This receptor binds to particles called low 
density lipoproteins (LDLs), which are the primary carriers of cholesterol in the 
blood (Jeon and Blacklow, 2005). Cholesterol is a waxy, fat-like substance that is 
produce in the body and obtained from foods that come from animals. 
Low density lipoprotein receptors sit on the outer surface of many types of cells, 
were they pick up low density lipoprotein circulating in the bloodstream and 
transport them into the cell. Once inside the cell, the low density lipoprotein is 
broken down to release cholesterol. After low density lipoprotein receptors drop 
off their cargo, they are recycled back to the cell surface to pick up more low 
density lipoproteins (Goldstein and Brown, 2001).  
Low density lipoprotein receptor plays a critical role in regulating the amount of 
cholesterol in the blood. They are particularly abundant in the liver, which is the 
organ responsible for removing most excess cholesterol from the body.  
The LDL-derived cholesterol acts at several levels, including suppression of 
transcription of HMGCoA reductase gene though the sterol regulatory element 
binding proteins (SREBPs) (Osbornet, 2000) pathway and acceleration of the 
degradation of the enzyme protein and suppresses transcription of the LDL 
receptor gene. The LDL derived cholesterol also regulates other processes in a 
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coordinated action that stabilizes the cell’s cholesterol contenent. It activates a 
cholesterol-esterifying enzyme, acyl CoA, cholesterol acyltransferase (ACAT) 
(Yamashita et al., 2014), so that excess cholesterol can be stored as cholesteryl 
ester droplets in the cytoplasm. The internalization of LDL is also regulated by 
PCSK9 protein (pro-protein convertase subtilisin/kexin type 9) (Rashid et al., 
2005) whose function is to induce the degradation of the LDL-R on the cell 
surface. The sterol regulatory element binding proteins, are localized at the 
membrane of the smooth endoplasmic reticulum and regulate the expression of 
over 30 genes involved in lipid metabolism. SREBPs consist of about 150 amino 
acids organized into three domains: an NH2 terminal domain, containing the 
binding site to the DNA, two hydrophobic trans-membrane segments and a COOH 
terminal domain, member of the link with SREBP cleavage-activating protein 
(SCAP), which acts as a sensor of the level of sterols. In the absence af sterols, the 
SCAP-SREBP escort him from the endoplasmatic reticulum (ER) to the Golgi 
apparatus, where they are located two different protease, SP1 (serine protease) and 
SP2 (zinc protease). The action of these two enzyme determines the release from 
the end of the –NH2 terminal nuclear SREBP (n SREBP) a fragment between 60-
70 kDa able to translocate to nucleus and interact with DNA. At nuclear level the 
nSREBP binds the sterol-responsive element (SRE)-1 of target genes involved in 
cholesterol homeostasis increasing their expression. When the cholesterol 
contenent in the cell increase, the SCAP changes in conformation, preventing the 
complex SCAP/SREBP moving to the Golgi apparatus to begin the sequence of 
events described above. 
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The number of low density lipoprotein receptors on the surface of the liver cells 
determines how quickly cholesterol (in form of low density lipoproteins) is 
removed from the bloodstream (Defesche, 2004). Mutation in the LDLR gene 
cause an inherited form of high cholesterol called familial hypercholesterolemia. 
More than 1.000 mutation have been identified in this gene. Some of these genetic 
changes reduce the number of low density lipoprotein receptors produced within 
cells. Other mutation distrupt the receptor’s ability to remove low density 
lipoproteins from the blood. As a result, people with mutation in the LDLR gene 
have very high blood cholesterol levels. The excess of cholesterol circulating  
through the bloodstream, it is deposited abnormally in the tissues such as skin, 
tendons, and coronary arteries, inducing a great increase in the risk  to have an 
heart attack (Ueda, 2005).  
Most people with familial hypercholesterolemia inherit one altered copy of LDL-
R gene from an affect parent and one normal copy of the gene from the other 
parent. These case are associate with an increased risk of early heart disease, 
typically beginning in a person’s forties or fifties. Rarely, a person with familial 
hypercholesterolemia is born with two mutated copies of the LDL-R genes. This 
situation occurs when the person has two affect parents, each of whom passes on 
one altered copy of gene. The presence of two LDL-R mutations results in a more 
severe form of hypercholesterolemia that usually appears in childhood (Marais et 
al., 2004; van Aalst-Cohen et al., 2004) 
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1.6 Lupin Protein  
Legume seeds are an abundant source of proteins and lupin is one of the richest. 
Lupin seed deserves largest interest as a result of its chemical composition and 
augmented availability in many countries in recent years. Lupin is a non-starch 
leguminous seed with a high protein content, almost as high as that of soybean 
(about 35% of the dry weight), and a relatively low oil content (Duranti et al., 
2008).  
Lupin is an economically and agriculturally valuable plant which is able to grow 
in many and different soils and climates. Interest in lupin production is increasing, 
due to its potential as a source of protein, or for pharmaceutical purposes, a green 
manure or, due to the high alkaloid content, as a natural component of plant 
pesticides (Sujak et al., 2006). Apart from the high protein content, lupin has a 
strong capability for nitrogen fixation and organic phosphorus release from soil 
and can be used in crop rotation during intensive grain production (Fan et al., 2002; 
Honeycutt, 1998). The best utilization of this plant can be extended to the 
production of protein concentrates, which, “when added to other food products or 
fodder”, can enrich their nutritional values, thus giving functional food (Archer et 
al., 2004; Batterham et al., 1986; Dijkstra et al., 2003; Guillaume et al., 1987; 
Linnemann and Dijkstra, 2002). Lupin seeds may also be a potential source of 
alimentary cellulose for the production of dietetic food. Among the lupin seed 
species, the most cultivated, primarily in Australia, is blue lupin (Lupinus 
angustifolius L.), while the typical European and South American varieties are 
yellow (Lupinus luteus L.) and white (Lupinus albus L. Fig.3) lupins. Blue and 
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yellow lupin seeds are mostly used for feed, while the white lupins are primarily 
grown for food uses.  
 
 
 
 
 
 
 
 
Fig. 3  (Lupinus albus L.) white lupin. 
 
1.6.1 Classification 
Most proteins of legume seeds are located in the storage vacuoles of the 
cotyledonary tissues and mostly, but not exclusively, belong to the family of the 
storage proteins which serve as nitrogen and carbon skeleton sources for the 
emerging plantlet (Duranti et al., 2008). White lupin seeds contain two classes of 
proteins, which according to Osborne’s classification, correspond to the albumin 
and globulin fractions. Seeds of white lupin have a protein content ranging from 
33% to 47%, according to genotype and location (Dervas et al., 1999). Oil content 
varies from 6% to 13% with a high concentration of polyunsaturated fatty acids 
(Huyghe, 1997). The presence of alkaloids proves to be non-toxic at low 
concentrations. Since most alkaloids of lupin are water-soluble, the alkaloid level 
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of lupin (0.5–4%) can be decreased to 0.04% by soaking in running water, brine 
or scalding. Also it has been possible to grow sweet genetic varieties with low 
alkaloid contents ranging from 0.008% to 0.012% (Allen, 1998) (Tsaliki et al., 
1999; Vasilakis and Doxastakis, 1999). Globulins are the typical salt soluble 
storage proteins of the seeds. This definition may not fit all cases, since both the 
solubility and the storage role of a protein are not always unequivocally defined, 
but for the sake of simplicity we will refer to the main lupin seed proteins as 
globulins. The first separation of lupin seed globulins dates back to the pioneering 
work of Blagrove and Gillespie (1975). These Authors used a cellulose acetate 
electrophoresis technique to separate four main fractions in L. albus and L. 
angustifolius. These fractions were named -, -, , -conglutins on the basis of 
their electrophoretic mobility. Further separations included isoelectric focusing, 
which illustrated the acidic nature of -, -, -conglutins and the basic nature of -
conglutin, and ion exchange chromatography which showed the extreme 
heterogeneity of the composition of these proteins (Casero, 1983; Duranti, 1981; 
Restani, 1981) as compared to other legume seed proteins. 
 
1.6.2-Conglutin 
1.6.2.1 Molecular characteristics  
-Conglutin is an unusual basic 7S protein, which is equally soluble in water and 
salt solutions. This protein represent 4-5 % of total proteins in mature lupin seeds 
(Duranti, 1981). At neutral pH, the prevalent form of -conglutin is a tetramer 
(Duranti et al., 2000), or a hexamer, according to other authors (Blagrove & 
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Gillespie, 1975). At acidic pH, the oligomer dissociates to a monomer of about 50 
kDa, with a quick transition around pH 5.0 (Duranti, 1986a, b). Each monomer is 
in turn composed of two disulphide linked subunits of 17 and 29 kDa (Restani, 
1981). Both subunits are heterogeneous as a probable result of post-translational 
proteolysis. However, heterogeneity is much less pronounced than in - and -
conglutins. Endogenous proteolysis converts the pro-polypeptide into the two 
mature subunits, as described for L. angustifolius -conglutin (Ilgoutz et al., 1997). 
However, the precise site of cleavage has not been identified yet, as trimming of 
the terminal regions of both subunits is likely to occur (Ilgoutz et al., 1997). 
Recently, four large and five small chains have been identified by proteomic 
analysis (Magni et al., 2007). The 29 kDa subunit is glycosylated with covalently 
linked mannose and glucosamine units. The corresponding glycosylation 
consensus sequence is present in both gene and resides in a cysteine-rich stretch in 
proximity to the N-terminal region. Two complete deduced amino acid sequences 
of -conglutin have been deposited. However, only the product of one gene 
(Q9FEX1_LUPAL) has been detected in the mature dry seeds (Scarafoni et al., 
2001). Lupin -conglutin is located in the protein bodies of developing lupin seeds 
(Pernollet, 1978; Shewry, 1995; Weber, 1980). However, the protein has also been 
detected in the extracellular apoplastic regions of germinating lupin cotyledons 
(Duranti, 1994). The unusual stability of -conglutin during seed germination and 
in “in vitro” tests with various proteolytic enzymes (Duranti et al., 1995) strongly 
suggests that it is not a storage protein. On the other hand, if the denatured protein 
is submitted to proteolytic attack, degradation by trypsin and other enzymes is 
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complete. This suggests an ‘‘all or none’’ cleavage mechanism of -conglutin 
(Duranti, unpublished data). Whether this feature reflects some functionality of the 
protein has yet to be established. The unusual extra-vacuolar location of -
conglutin adds further evidence that this protein probably plays a non storage role 
(Citharel, 1988; Duranti et al., 1991; Duranti, 1994). Intense research activity of 
our group is devoted to elucidating the physiological role of this protein. -
Conglutin displays further unique properties of its own: it binds divalent metal 
ions, especially Zn++ and Ni++ (Duranti et al., 2001) which have been shown to 
promote the refolding of the denatured protein (Duranti et al., 2002) and, 
independently, insulin with a Kd of     10-5 M over a wide range of pH values 
(Magni et al., 2004). 
 
1.6.2.2 The glucose lowering activity of conglutin 
Lupin -conglutin is a protein known to elicit a significant glucose decrease 
response. Although the mechanism of action of this dietary protein is still far from 
being understood, these experimental findings represent the rationale behind the 
attribution of anti-diabetic properties to lupin seeds, as claimed by traditional 
pharmacopoeia. 
Some years ago, the ability of this protein to lower plasma glucose concentrations 
upon glucose overload in mice was first shown (Magni et al., 2004). Since then, 
experimental evidences on the peculiar biological effects of -conglutin have 
accumulated. In particular, the effect of -conglutin on the activation of 
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differentiating myocyte signaling pathway closely resembled that of insulin 
(Terruzzi et al., 2011).  
As a matter of facts,-conglutin cell stimulation resulted in the persistent 
activation of protein synthetic pathway kinases, and increased glucose transport, 
GLUT4 translocation, as well as muscle-specific gene transcription regulation. 
Further studies on the oral administration of -conglutin to animal models and 
healthy humans confirmed its remarkable capacity of decreasing glycaemia 
(Bertoglio et al., 2011). In a study aimed at identifying the metabolic fate of the 
protein, “in vitro”  and “ex vivo” approaches showed that the protein can be 
transcytosed through a Ca-Co2 cell monolayer and cross the intestinal barrier in 
an intact form (Capraro et al., 2011). Other functional “in vitro”  studies showed 
the peculiar resistance of this protein to a number of proteolytic enzymes (Capraro 
et al., 2009). This feature supports the hypothesis that at least part of the protein 
may reach the intestinal lumen in an active form and thus exert systemic biological 
activity (Capraro et al., 2011). 
-Conglutin was found to interact “in vitro” with insulin with a Kd around 7 x 10-
5 M and, most importantly, to significantly reduce plasma glucose in rodents 
(Magni et al., 2004). Since insulin-binding to its own receptor causes a series of 
phosphorylation/dephosphorylation reactions, which lead the insulin signal from 
the receptor to the final metabolic and myogenic pathway. It was hypothesize, in 
fact, that the effect of -conglutin on blood glucose is due to an insulin-mimetic 
effect of the protein at the level of the intracellular pathway of the insulin 
receptor/IRS-1/PI-3-kinase, eventually leading to the recruitment and 
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translocation of GLUT4. Secondly, as insulin promotes muscle protein synthesis 
induced muscle anabolism, it was hypothesize the activation by -conglutin.   
 
1.7 Diabetes Mellitus 
On September 14, 2011, the International Diabetes Federation announced that 336 
million people worldwide now have type 2 diabetes, and that the disease is 
responsible for 4.6 million deaths each year, or one death every seven seconds. It 
affects 12% of US adults and >25% of those over the age of 65. Diabetes is no 
longer restricted to the Western world, and the greatest increases in disease 
incidence in the next few decades are expected to be in China and India. These 
prevision serve to emphasize that there is currently a fast-growing diabetes 
pandemic. This is a major healthcare problem because diabetes increases the risk 
of heart disease, stroke, and microvascular complications such as blindness, renal 
failure, and peripheral neuropathy. Consequently, it places a severe economic 
burden on governments and individuals: the cost of diabetes and its complications 
amounts to $ 612 million per day in the USA alone. Diabetes mellitus is a chronic 
illness that requires continuing medical care and ongoing patient self-management 
education and support to prevent acute complications and to reduce the risk of 
long-term complications. Diabetes care is complex and requires multifactorial risk 
reduction strategies beyond glycemic control. 
The classification of diabetes includes four clinical classes: 
 Type 1 diabetes (results from -cell destruction, usually leading to absolute 
insulin deficiency) 
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 Type 2 diabetes (results from a progressive insulin secretory defect on the 
background of insulin resistance) 
 Other specific types of diabetes due to other causes, e.g., genetic defects in 
-cell function, genetic defects in insulin action, diseases of the exocrine 
pancreas (such as cystic fibrosis), and drug- or chemical-induced (such as 
in the treatment of HIV/AIDS or after organ transplantation) 
 Gestational diabetes mellitus (GDM) (diabetes diagnosed during pregnancy 
that is not clearly overt diabetes) 
Diabetes is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both. The chronic 
hyperglycemia of diabetes is associated with long-term damage, dysfunction 
of different organs, especially the eyes, kidneys, nerves, heart, and blood 
vessels. 
More pathogenic processes are involved in the development of diabetes. These 
range from autoimmune destruction of the β-cells of the pancreas with 
consequent insulin deficiency to abnormalities that result in resistance to 
insulin action. The basis of the abnormalities in carbohydrate, fat, and protein 
metabolism in diabetes is deficient action of insulin on target tissues. Deficient 
insulin action results from inadequate insulin secretion and/or diminished 
tissue responses to insulin at one or more points in the complex pathways of 
hormone action. Impairment of insulin secretion and defects in insulin action 
frequently coexist in the same patient, and it is often unclear which 
abnormality, if either alone, is the primary cause of the hyperglycemia 
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For more time, the diagnosis of diabetes was based on plasma glucose criteria, 
either the fasting plasma glucose (FPG) or the 2 hours value in the 75 gr oral 
glucose tolerance test (OGTT) (Association, January 2010 ) . People with diabetes 
should receive medical care from a team that may include physicians, nurse 
practitioners, physician’s assistants, nurses, dietitians, pharmacists, and mental 
health professionals with expertise and a special interest in diabetes. It is essential 
in this collaborative and integrated team approach that individuals with diabetes 
assume an active role in their care. 
 
1.7.1 Insulin  
Insulin is known as potent anabolic hormone and is essential for appropriate tissue 
development, growth, and maintenance of whole-body glucose homeostasis. 
Insulin  is secreted by the β cells of the pancreatic islets of Langerhans in response 
to increased circulating levels of glucose and amino acids after a meal. This 
hormone regulates glucose homeostasis at many sites, reducing hepatic glucose 
output (via decreased gluconeogenesis and glycogenolysis) and increasing the rate 
of glucose uptake, primarily into striated muscle and adipose tissue. In muscle and 
fat cells, the clearance of circulating glucose depends on the insulin-stimulated 
translocation of the glucose transporter GLUT4 isoform to the cell surface. Insulin 
also profoundly affects lipid metabolism, increasing lipid synthesis in liver and fat 
cells, and attenuating fatty acid release from triglycerides in fat and muscle. Insulin 
resistance occurs when normal circulating concentrations of the hormone are 
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insufficient to regulate these processes appropriately. Thus, by definition, insulin 
resistance is a defect in signal transduction.  
 
1.7.2 The insulin receptor 
The insulin receptor consists of two  subunits and two  subunits that are 
disulfide linked into a 22 heterotetrameric complex. Insulin binds to the 
extracellular  subunits, transmitting a signal across the plasma membrane that 
activates the intracellular tyrosine kinase domain of the  subunit. The insulin 
receptor (IR) then undergoes a series of intramolecular transphosphorylation 
reactions in which one  subunit phosphorylates its adjacent partner on specific 
tyrosine residues (Pessin and Saltiel, 2000).  
 
1.7.3 Insulin signaling pathway 
Following binding of insulin to the extracellular portion of the IR, the second 
messenger system involved in insulin signaling diverges into separate pathways 
that regulate distinct biological effects. These specific second messenger proteins 
are also employed in mediating the effects of a variety of other hormones. Thus, a 
specific and coordinated cellular response to insulin stimulation requires the 
integration of a full network of signaling processes (Taniguchi et al., 2006). The 
substrate tyrosine kinase activity of the IR initiates a cascade of cellular 
phosphorylation reactions that regulate protein interactions and enzymatic 
activities. Substrates of the IR include the insulin receptor substrates IRS-1 and 
IRS-2, as well as Shc (Src homology collagen) and APS (adaptor protein with a 
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PH and SH2 domain) (Taniguchi et al., 2006). These phosphorylated substrates 
then serve as docking molecules that bind to and activate cellular kinases, initiating 
the divergent signaling pathways that mediate cellular insulin action. The pathway 
of insulin signaling is that the stimulation of glucose transport and most other 
metabolic effects of insulin are regulated by activation of the phosphatidylinositol 
3- kinase (PI3K) pathway, facilitated by binding of the regulatory subunit of PI3K 
to phosphotyrosine residues on IRS-1. The ultimate effector system for regulating 
glucose disposal is the translocation of GLUT4-containing vesicles to the plasma 
membrane.  
 
1.7.4 The association of PI-3K with IRS proteins and activation of Akt/PKB 
The predominant function of the insulin receptor substrate (IRS) proteins seems to 
be the activation and/or regulation through many pathways of the phosphoinositide 
3-kinase (PI3K). PI3K is a heterodimer with two separate subunit, regulatory and 
catalytic subunits (p85 and p110 respectively). In its resting state, PI3K is present 
as an inactive p85-p110 complex. After the activation of a receptor tyrosine kinase 
(RTK), due to the phosphorylation of its cytoplasmic tail, the p85-p110 complex 
is recruited to the receptor by interaction of an SH2 domain on p85 with 
phosphotyrosine residues on the RTK (Fruman et al., 1998). This interaction is 
believed to release the inhibitory effects of p85 on the catalytic p110 (Yu et al., 
1998). P110 is able to interact with its lipid substrates, the phosphatidylinositol, 
and convert PIP2 to PIP3. Recruitment of PI3K by RTK also puts p110 in close 
proximity to these lipid substrates residing in the plasma membrane. The major 
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exception to this reaction is that PI3K can be activated by signal adapter proteins, 
such as IRS-1 and IRS-2, rather than by RTKs themselves (White, 2002). It is 
important to note, IRS-mediated activation of PI3K requires that phosphorylated 
YMXM motifs occupy both SH2 domains within p85. Generation of PIP3 by 
activated PI3K near the plasma membrane results in interaction with, and 
subsequent phosphorylation of, its primary substrate Akt. Akt requires, for its full 
activation, the phosphorylation of the residue of Ser473 and the residue Thr308 and 
interacts with the phosphatidynol3, 4biphospate (PI3,4P2), 4,5 trisphosphate 
(PI3,4,5P3), produced by PI3K. These phospholipids are essential for its activation: 
their interaction with the PH domain of Akt modifies the conformation and makes 
that Akt is recruited to the cell membrane, where the protein complex Rictor-
mTOR (Target of its mammalian rapamycin) phosphorylates at ser473 level and it 
facilitates the subsequent phosphorylation, at the level of treonina308, by PDK1 (3-
phosphoinositide dependent protein kinase-1) (Sarbassov et al., 2005). One of the 
major substrates of Akt is glycogen synthase kinase-3 (GSK-3), which participates 
in the regulation of glucose homeostasis regulating the synthesis of glycogen. The 
levels of glycogen (synthesized mainly in the liver and muscle) are tightly 
regulated by the action of the enzyme glycogen synthase (GS), which synthesizes 
and its antagonist, the enzyme glycogen phosphorylase. In basal conditions, GSK-
3 inhibits glycogen synthesis by blocking the activity of GS inhibitory 
phosphorylation pathway. The activation of the insulin pathway leads to 
IRSs/PI3K/Akt inhibitory phosphorylation of GSK-3 at residues Ser regulators 21 
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(on  isoform of GSK-3) and Ser 9 (on  isoform of GSK-3). This activates the 
GS and the glycogen synthesis (Lee and Kim, 2007).  
 
1.7.5 Insulin resistance 
Tissue insulin resistance predisposes an individual to significant health risks in 
addition to its role in the pathogenesis of type 2 diabetes mellitus (Groop, 1999). 
In humans, insulin-stimulated muscle glucose disposal rates vary widely across the 
normal population, and the insulin-resistant state refers to individuals in the lower 
end of a normal distribution, rather than a discreet pathological condition. In “in 
vivo”, muscle insulin sensitivity is regulated on a long-term basis by factors such 
as obesity, and is altered in a more rapid manner by changes in dietary habits and 
physical activity (Barnard, 1992).Though more difficult to quantify, there is also 
evidence for genetic or intrinsic differences in muscle insulin sensitivity (Groop, 
1999). In any individual, therefore, the degree of insulin sensitivity is determined 
by the interaction of numerous factors, both genetic and environmental. Both acute 
and chronic regulation of tissue insulin sensitivity can occur via multiple pathway 
through which the cellular mediators of insulin signaling can be altered by protein 
interactions and other modifications. 
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2 
AIM  
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Food proteins are considered as source of bioactive peptides and amino acids that 
can exert physiological functions to promote health and prevent chronic diseases, 
such as lipid disorders (Lovati, 2006) diabetes (Lovati et al., 2012), hypertension 
(Matoba et al., 2001) cancer (Chiesa et al., 2008; De Mejia, 2010 ; Galvez et al., 
2001) and obesity (Martinez-Villaluenga et al., 2010) which are typical of 
industrialized societies. It is known that during gastrointestinal digestion or food 
processing, these peptides are released from the parent protein and act as 
regulatory compounds with hormone-like activities (Martinez-Villaluenga et al., 
2010). Soybean (Glycine max) and white lupin (Lupinus angustifolium) comprise 
the most widely grown legume crops in the world. In addition to being an 
invaluable source of oil and protein for food and feed, many papers from our group 
pointed out the positive effect of soybean and white lupin proteins on lipid and 
glucose metabolism.  Despite intensive studies in this area, the protein molecules 
directly responsible for the observed effect have not been unequivocally identified 
nor with regard to the protein of soya nor with regard to those of white lupin. 
 
The aim of the present doctorate thesis is to evaluate in “in vitro” and “in vivo” 
experiments the ability of polypeptides from soybean and from white lupin to 
interact with the molecular mechanisms involved in the regulation of plasma and 
tissue lipids as well as in the glucose homeostasis control. 
 
For soybean proteins, the ’ subunit of the soybean 7S globulin, the so called -
conglycinin, was shown to have a key role in the up-regulation of high affinity-
54 
 
LDL receptors, in “in vivo” and “in vitro” systems (Duranti et al., 2004; 
Maruyama et al., 1999) suggesting that biologically active peptides, capable of 
modulating lipid homeostasis, are likely to be produced by cell and gastrointestinal 
enzymes. The native 7S globulin is a randomly assorted hetero-trimer,, ’ and 
 subunits , with molecular mass of 150-200 kDa (Manzoni et al., 2003). The and 
’ chain consist of a core regions with a high degree of homology (87%) and 
extension regions (, 125 residues; ’, 141 residues) exhibiting lower homology 
(57%), whereas subunit consists of only a core region that has homology with  
and ’ core regions (75 and 72 %, respectively) (Lovati et al., 2000). Although, 
the results from “in vitro” and “in vivo” experiments justify the lipid-lowering 
activity of ’ subunit, a related concern is the biological fate of this polypeptide 
“in vivo” because it seems unlikely that it crosses the intestinal barrier with no 
modification. We hypothesized, in fact, that peptides, deriving from the activity of 
gastric/intestinal enzymes on soybean proteins, might be absorbed by the 
enterocytes and reach the liver through the blood stream, where they elicit the 
biological effect (Lovati et al., 2000; Lovati, 1998; Manzoni et al., 2003) . Our 
research group has been following two different approaches to identify the active 
peptide/s involved in the lipid regulation. The first one has been to reduce the 
length of the polypeptide chain of ’ subunit by a biotechnological process 
obtaining an extension form of ’ chain, roughly covering one third of the full-
length polypeptide from N-terminus, which has been shown to up-regulate the 
LDL-R in Hep G2 cells (Consonni et al., 2011). The second approach has been to 
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make a screening of peptides with amino acid sequences occurring in ’,  and  
subunits of soy -conglycinin, and test their biological effect “in vitro”. These 
peptides have been evaluated for their effect on the expression of LDL receptor, 
sterol regulatory element binding protein-2 (SREBP-2) and hydroxymethylglutaril 
coenzyme A reductase (HMGCoA red) in HepG2 cells. Moreover, the peptide 
which resulted more promising among the different compounds has been tested in 
“in vivo” experiment in order to evaluate its potential on lipid homeostasis in a rat 
model of human hypercholesterolemia. 
Recently new data on the potential of -conglutin, a seed glycoprotein with a 
molecular weight of 47 kDa, on the glucose metabolism are emerging. Since the 
“in vitro” interaction of -conglutin with mammalian insulin has been described 
in the present study the effect of an oral dose of this protein was studied in an 
animal model of diabetes in order to evaluate its ability to modulate the plasma 
glucose rise. Moreover in “in vitro” experiments the ability of -conglutin to 
interact with cell compartment and to interfere in the insulin pathway has been 
followed in order to ascertain whether the protein was characterized by insulin-
like property. 
Although, the data presented in this report need to be confirmed by human studies 
the potential of peptides from ’ subunit of soybean as well as that of lupin seed 
–conglutin to control plasma lipids and  glycaemia could be considered before 
developing new therapeutic strategies for the prevention or regression of lipid and 
glucose metabolism modifications. 
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            3 
MATHERIALS 
AND METHODS 
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3.1 Materials 
3.1.1 Isolation of -conglutin 
Dry mature seeds of white lupin (L. albus L, var. Multitalia) were kindly provided 
by Dr Massimo Fagnano, University of Naples, Naples, Italy. Type F, a -
conglutin-enriched lupin protein isolate, prepared as described in Bez et al (Bez, 
2005), was kindly supplied by Fraunhofer Institute (Munich, Germany). This 
preparation, the composition of which is detailed in the cited reference, contained 
about 80% protein and was used as such in the “in vivo” experiments. A 
laboratory-scale purified -conglutin was utilized in the “in vitro” assay. The 
procedure for -conglutin purification, as described by Duranti et al. (Duranti et 
al., 1994) was slightly modified to improve the homogeneity of the preparation. In 
particular, after conventional chromatographic steps, which included gel 
permeation chromatography, ion exchange chromatography on both Whatman 
DE52 diethylaminoethyl-cellulose and carboxymethylcellulose, a further step of 
metal affinity chromatography was added. For this purpose, the protein solution 
was loaded onto a nickel column (NiNTA-Agarose; Qiagen, Milan, Italy) 
equilibrated in 50 mM-Tris–HCl, pH 7.4, containing 0.5 M NaCl. The protein 
bound to the matrix was subsequently eluted with 50 mM sodium acetate, pH 4.5, 
containing 0.5 M NaCl. The purified protein was desalted by dialysis against 
MilliQ water and freeze dried. For the estimation of purified -conglutin 
concentrations, optical measurements at 280 nm were made. The extinction 
coefficient of 0.733 for a solution of 1 mg/ml was used (Capraro et al., 2010). SDS-
PAGE was carried out on 12% polyacrylamide gels, according to Laemmli 
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(Laemmli, 1970) under reducing conditions using a mini-Protean II cell (Bio-Rad, 
Milan, Italy). Samples were heated at 100 °C for 5 min before loading. The gels 
were stained with Coomassie Blue. Densitometric scanning of the gel was carried 
out by ImageMaster 1D software (Amersham Pharmacia Biotech, Milan, Italy). 
 
3.1.2 Isolation of soybean 7S globulin and ’ subunit 
 For the isolation of the 7S globulin, a modification of a published procedure (Wu 
and 1999) was used. Our procedure consisted in the selective extraction of the 7S 
globulin with 7 mM NaHSO3 at 4°C with stirring for 16 h. The flake weight to 
buffer volume ratio was 1:15. Centrifugation at 8000 xg for 1 h at the same 
temperature allowed the recovery of a supernatant, which consisted essentially of 
7S globulin, and a pellet containing all insoluble materials, including the glycinin 
fraction and a residual amount of 7S globulin. The 7S globulin was recovered from 
the supernatant by 40% aqueous ethanol precipitation and centrifugation as above. 
The pellet was then freeze-dried. Isolation of the 'subunit: Urea (8 M) in 50 mM 
Tris-HCl, pH 7.4, containing 0.5 M NaCl (loading buffer) was used as a denaturing 
agent to dissociate the 7S globulin subunits. The resulting solution was applied to 
a MAC matrix coupled with Zn2+, in a ratio of 30 g of 7S globulin/L of resin. The 
resin was thoroughly washed with the loading buffer to elute the unbound fraction. 
The bound fraction was subsequently eluted with 0.1 M imidazole in the loading 
buffer. The recovered 7S globulin ’subunit was then precipitated and washed 
with 40% aqueous ethanol before freeze drying. 
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This procedure was applied to 250 g of defatted soybean flakes to obtain 5 g of ’ 
subunit. The whole procedure, has been patented (Bradford, 1976; Duranti, 2002). 
Total soybean proteins for SDS-PAGE analysis were directly extracted with 
sample denaturing buffer containing 3.75% SDS and 350 mM 2-mercaptoethanol. 
Protein concentrations were determined with the Bradford method (Bradford, 
1976), using bovine serum albumin as the standard protein.  
 
 
 
 
 
 
 
Figure.1: 7S soybean globulin subunits: homology grade  
 
3.1.3 7S ’ extension 
An ’polypeptide consisting of 216 amino acid residues from the N-terminus, 
containing the extension region plus a stretch of the core region (Fig. 1) was cloned 
and over-expressed in Pichia pastoris. The yield of the recombinant polypeptide, 
which was termed ’E, was 8-fold greater than the truncated version previously 
obtained. The ’ E polypeptide was purified by conventional biochemical 
techniques to make it available for biological assay. The recombinant polypeptide 
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was used in “in vitro” and “in vivo” experiments to evaluate its potential on lipid 
homeostasis. 
 
3.2 Sinthetic soy peptides  
From database searching (http://www.uniprot.org), we identified five peptides, 
belonging to ’,  and  subunit of 7S soy (Glycine max) globulin with the aim to 
investigate the potential of soybean peptides on cholesterol homeostasis, and anti-
inflammatory activities as well as on anti-adipogenic and anti-oxidant properties 
in different cell lines. 
Synthetic peptides A and B (purity > 98%) were purchased by EZBiolab Inc., IN 
46032, USA. Peptides C, D and E were custom synthesized by GenScript 
(Piscataway, NJ, USA) (Table 1). 
 
Amino acid sequence of synthetic peptides from soybean -conglycinin 
Peptide Sequence MW pI Subunit 
A SEEEEEDQ 994 3.4 ’-extension 
B QKEEEKHEWQ 1370 4.9 ’-extension 
C RKQEEDEDEEQQRE 1847 4.3 ’ 
D EITPEKNPQLR 1324 6.2 ’, ,  
E KNPQLR 754 11.0 ’, ,  
S= Ser; E= Glu; D= Asp; Q= Gln; K= Lys; H= His; W= Trp; R= Arg; I= Ile; T=Thr; N= Asn; P= Pro; L= Leu;  
Table 1: Amino acid sequence of synthetic peptides from soybean -conglycinin 
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3.2.1 NPDNDE synthetic peptide 
A synthetic peptide corresponding to position 314-319 of ’ chain 7S soy globulin 
was purchased by EZBiolab Inc as previously reported and used in “in vitro”  and 
“in vivo”  experiment to evaluate its potential on cholesterol homeostasis. The 
purity was greater than 98%. 
 
3.3 Fluorescein isothiocyanate (FITC)-tagged proteins. 
-Conglutin, was incubated overnight at 4°C in conjugation buffer (0.5 mM 
carbonate/bicarbonate, pH 9.5) in the presence of FITC (30 μg/mg protein) under 
stirring. Unreacted dye was removed using a PD 10 column by elution with PBS. 
The integrity of tagged proteins was verified by SDS gradient gel electrophoresis 
(7.5–17.5%). 
 
3.4 Animal and Diet  
Male Sprague–Dawley CD rats (Charles River Laboratories Italia Srl, Calco-
Lecco, Italy), body weight (b.w.) 125–150 g (5-6 week), were housed in a room 
with controlled lighting (12 h/d), constant temperature (20-22 °C) and relative 
humidity (55–65%).  
 
3.4.1 Hypercholesterolemic diet  
After their arrival from shipment an adjustment period to the new home condition 
was allowed during which they were fed a standard diet (pelleted commercial non-
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purified diet (4RF21-Mucedola, Italy). Rats were then divided into five groups of 
9 rats on the basis of b.w. and transferred to a Nath’s hypercholesterolemic (HC) 
diet (1 g/100 g cholesterol and 0.5 g/100 g cholic acid). To distinguish effects on 
plasma lipids as a function of altered food intake were included a group of rats 
pair-fed the control diet. 
After 2 week of HC diet rats were allocated to treatment groups on the basis of 
b.w. and plasma lipids so that the distribution among the groups was similar.  
 
3.4.2 Glucose overloading 
Following a two day adaptation period, during which they were fed a standard diet 
(pelleted commercial non-purified diet - Mucedola 4RF21; Settimo Milanese, 
Milan, Italy), the animals were given 10% D-glucose in drinking-water for the 
entire experimental period. The rats had free access to water. The mean daily water 
intake was between 20 and 30 ml/rat, estimating an average daily intake of D-
glucose about 2–3 g. After 1 week, the animals were divided in two groups of 
twelve rats according to their b.w. and plasma glucose concentrations, so that the 
distribution between the groups was similar.  
 
3.5 Animal’s treatment 
All procedures involving animals and their care were conducted in accordance 
with institutional guidelines that are in compliance with national (D.L. no. 116, 
G.U. Suppl. 40, 18 February 1992, Circolare no. 8, G.U. July 1994) and 
international laws and policies (EEC Council Directive 86/609, OJL 358, 1, 12 
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December 1987; Guide for the Care and Use of Laboratory Animals published by 
the US National Institute of Health-NIH Publication no. 85-23, revised 1996). 
 
3.5.1 -Conglutin treatment  
The animals were daily treated (at 09.00 hours) by gavage for three weeks as 
follows: one group (D-glucose) received only the vehicle (1% 
carboxymethylcellulose), whereas the other group (D-glucose + -conglutin) 
received 100 mg/kg b.w. type F, corresponding to 28 mg/kg b.w. -conglutin in 
carboxymethylcellulose (CMC). A third group of rats received only the vehicle 
without D-glucose in drinking-water (controls). Food intake and b.w. were 
monitored weekly. 
 
3.5.2 7S ’ extension treatment  
The animals were daily treated (at 09.00 hours) for four  weeks by gavage as a 
suspension in a 1% (w/v) aqueous solution of CMC as follows: IDN 6442 20 
mg/kg b.w. (15.42 mg of 7S-’ corresponding to 5.53 mg '/kg b.w., IDN 6443  
25 mg/kg and 50 mg/kg b.w. (5,65 mg /kg b.w. and 11,3 mg/kg b.w. of protein), 
clofibrate (Sigma-Aldrich, Milan, Italy) 200 mg/kg b.w.. Control groups on either 
the standard or the hypercholesterolemic diet received vehicle only. Food intake 
was monitored daily whereas variations in b.w. weekly.  
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3.5.3 NPDNDE treatment  
The animals fed casein-cholesterol (HC) diet, divided into three groups (12 rats 
each) homogeneous for plasma lipids, were daily treated for three weeks (21 day) 
by gavage as a suspension of 1% (w/v) aqueous solution of CMC as follows: 
synthetic peptide NPDNDE 5 mg/Kg b.w., soybean 7S alfa’20 mg/kg b.w. or 
clofibrate (Sigma-Aldrich, Milan, Italy) 200 mg/kg b.w..  

"In vivo"-Conglutin experiment 
3.6 Glucose consumption 
At the end of the experimental period, glucose loading was carried out on 10 h 
fasted animals. At time 0, each rat was given 2 g/kg b.w. D-glucose, administered 
orally. Blood samples were withdrawn from the tail vein of each rat under light 
diethyl ether anesthesia at 30, 60, 120 and 180 min following the carbohydrate 
load. Aliquots of serum were stored at – 20°C until assayed. Glucose was 
determined by enzymatic method (Sigma-Aldrich, Milan, Italy). 
To estimate the degree of insulin resistance (IR), the homeostasis model 
assessment (HOMA) was used as an index of IR according to Midaoui & De 
Champlain (20). The HOMA-IR index was calculated using the following 
equation:   
                             fasting insulin U/ml x fasting glucose mmol/22.5 
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"In vivo"S'experiment 
3.7 Blood and liver collection  
At the end of the experimental period, rats were anesthetized and whole blood was 
collected from the abdominal aorta in the presence of EDTA (1mg/ml). Plasma 
samples were kept at –20°C for subsequent determinations. Immediately after 
sacrifice the liver was collected, washed with ice-cold 150 mM NaCl, fast freezing 
in liquid nitrogen and placed at −80°C for long-term storage. A small portions of 
liver were quickly placed in RNAlater™ solution for tissue archiving without risk 
of RNA degradation. The Institutional guides for the care and use of laboratory 
animals were followed, and the experiments were supervised by the Laboratory 
Animal Welfare Service.  
 
3.8 Lipoprotein isolation and analysis 
Pool of plasma from three rats in the same experimental group were used for 
lipoproteins fractionation by sequential preparative ultracentrifugation. 
Ultracentrifugation was performed at 5°C in a Beckman Model L-5-50B 
ultracentrifuge (Beckman Instruments, Palo Alto, CA) with a 50 titanium rotor. 
Lipoproteins were separated into very low density lipoprotein (VLDL) by 
centrifugation for 18 h at 100,000 xg. For isolation of low density lipoprotein 
(LDL, 1.006<d<1.045 g/mL) and high density lipoprotein (HDL, 1.045<d<1.21 
g/mL) the centrifugation was done at 100,000 xg for 20h and 24 h respectively. 
Isolated lipoprotein fractions were dialyzed against 0.02 M phosphate buffer (pH 
7.4) containing 0.15 M NaCl, 0.01% Na2EDTA and 0.02% NaN3 (Havel et al., 
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1955). Cholesterol and triglyceride concentrations in plasma and in lipoprotein 
fractions as well as glucose levels were determined by enzymatic methods (Horiba 
ABX S.A.S, Italy). 
 
3.9 Liver lipids extraction.  
Immediately after blood collection, livers were perfused in situ with ice-cold saline 
then removed and weighed. Liver from three rats for group were pooled and lipids 
were extracted with chloroform/methanol (2/1, v/v) according to the method 
described by Folch (Folch et al., 1957). Duplicate pieces of 0.25 g frozen liver 
were cut up and homogenized with 10 mL of a 2:1 chloroform/methanol solution 
with Ultra-Turrax T25. The homogenate was vortexed for 15 s every 5 min for a 
total of 30 min. Then filtered and the filtrate washed with 5 mL 
chloroform/methanol solution. Subsequently, 0.84 g/L KCl was added, followed 
by further vortexing and subsequent resting for 30 min. After removal of the top 
(water) layer, the bottom layer was evaporated to dryness by flushing with 
nitrogen. 
 
3.10 Cholesterol and triglycerides liver measurement  
Cholesterol and triglycerides content in the lipid residue was measured by 
enzymatic color method, after total lipids were dissolved in Triton X-100 (Carr et 
al., 1993). Results are expressed as milligrams triglyceride or cholesterol per gram 
liver (wet wt).  
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3.11 RT-PCR experiments.  
Total RNA was extracted from frozen liver using RNeasy Mini Kit (QIAGEN 
S.r.l., Italy) according to instruction of the manufacturer and resuspended in 40 µl 
of water. All RNA samples were examined as to their concentration, purity and 
integrity based on absorbance ratio at 260/280 nm and at 230/260 nm. Overall 
sample integrity was confirmed by agarose gel electrophoresis, showing sharp and 
intense 18S and 28S ribosomal RNA bands with a total absence of smears. For 
real-time PCR determinations five micrograms of total RNA were retrotranscribed 
whith “iScript cDNA Synthesis Kit” (Bio-Rad Laboratories Srl, Italy) according 
to instruction of the manufacturer. Real-time RT-PCR assays were performed by 
the TaqMan technology on an ABI PRISM 7000 SDS (Applied Biosystems, 
Weiterstadt, Germany). Each PCR reaction contained 5 μL cDNA template 
(corresponding to approximately 50 ng of the total extracted RNA).  
We assessed LDL-R and 18 S mRNA expression levels using the R.norvegicus 
LDLR, and Eukaryotic 18S rRNA Endogenous Control TaqMan® Gene 
Expression Assays (Inventoried) (Applied Biosystems® by Life Technologies 
Italia). The comparative Ct method was used to quantify the results. 
 
-Conglutin experiments in cells cultures 
3.12 Cells 
Hepatoma cell line (HepG2) was obtained from American Type Culture Collection 
(Rockville, MD, USA). Cells were grown in monolayer in 75 cm2 flasks and 
maintained at 37 °C in a humidified atmosphere of 95% air, 5% CO2 in Dulbecco’s 
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minimum essential medium (DMEM; 5.5 mM glucose) containing 10% fetal 
bovine serum, non-essential amino acids (1 %, v/v), penicillin (105 U/l) and 
streptomycin (0.1 g/l), and of sodium pyruvate (0.11 g/l). 
 
3.13 Glucose consumption 
To evaluate glucose consumption 2 day before the experiments HepG2 cells were 
plated in twenty-four-well plates (1.5x 105 cells/well) with some left blank. Cells 
were starved in serum-free DMEM supplement with 0.2% bovine serum albumin 
(BSA) and glucose at various concentrations (5.5, 11.1 and 16.5 mM). After 12 h, 
the medium was removed and the cells were exposed to 10-5 M -conglutin with 
or without metformin (10 nM) and/or insulin (100 nM), including the blank wells, 
for 24 or 48 h. At the end of incubation periods, glucose concentrations in the 
medium was determined by the glucose oxidase method. The amount of glucose 
consumption was calculated by subtracting the glucose concentration of cells 
treated with different compounds from the cells treated with vehicle (Li et al., 
2007). In the same experimental conditions cell viability was evaluated by 
methyltetrazolium salts assay, essentially as described by Lovati et al. (Lovati et 
al., 2000).  
 
3.14 FACS Analysis 
3.14.1 Glucose uptake by HepG2 cells 
The glucose uptake was measured by using the fluorescent glucose analogue 2-[N-
(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2-deoxyglucose (2-NDBG) at 50 M 
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concentration. The assay was carried out as previously described with minor 
modifications (Zou et al., 2005) . Cells were incubated in DMEM containing 11.1 
mM glucose in the absence/presence of 2-NBDG or 2-NBDG with 10-5 M -
conglutin or 100 nM insulin for 6 h. At the end of incubation, the 2-NBDG uptake 
reaction was stopped by removing the incubation medium and washing the cells 
twice with pre-cold phosphate buffered saline (PBS), as described (Lovati et al., 
2012). Cells in each well were subsequently re-suspended in PBS and maintained 
at 4 C° for flow cytometry analysis, which was carried out by using a FACScalibur 
(Becton Dickinson, Franklin Lakes, N.J., USA) flow cytometer. The fluorescence 
intensity of 2-NBDG present into the cells was recorded on the FL1 channel, 
following elimination of the dead cells labeled with propidium iodide; for each 
measurement the data from 5,000 single cell events were detected.  
To assess cell viability, culture media from cells exposed to the different 
compounds were tested by methyltetrazolium salts assay, as described by Lovati 
et al. (Lovati et al., 2000). 
 
3.14.2 Effect of endocytosis inhibitor on FITC- -conglutin  
HepG2 cells grown in DMEM containing 11.1 mM glucose were pretreated for 30 
minutes with or without different inhibitors of caveolae/lipid raft-mediated 
endocytosis [filipin (5g/ml) and genistein (200 M)], of clathrin-mediated 
pathway [chlorpromazine (25 M), methyl--cyclodextrin (5 mM) and of 
macropinocytosis [amiloride (5 mM)]. The cells were then incubated with FITC-
-conglutin (10-5 M) for 4 h at 37°C in the presence of inhibitors. After incubation 
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cells were washed with PBS 1x twice and detached by trypsinization. After 
centrifugation, cells were washed, resuspended in PBS and maintained at 4 C° for 
flow cytometry analysis, which was carried out by using a FACScalibur (Becton 
Dickinson, Franklin Lakes, N.J., USA) flow cytometer.  
 
3.15 Confocal Analysis  
3.15.1 Time course of -Conglutin uptake  
HepG2 cells were grown on glass coverslips and incubated in DMEM containing 
11.1 mM glucose with/without 10-5 M  -conglutin for 30 min, 3, 6 and 24 h. 
Afterwards, they were fixed with 4% paraformaldehyde (PMF), permeabilised 
with Tryton X-100 0.1% and washed with PBS. Labelling was carried out 
overnight at 4°C with anti--conglutin serum 1:100 v/v in PBS, followed by 2 h 
incubation at 20 °C in anti-rabbit conjugated with Alexa-Fluor 568 (1:200 v/v in 
PBS) and staining with DAPI (1:20.000 in PBS). Finally, coverslips were sealed 
with Mowiol on glass slides and examined with a video-confocal microscope 
(Vico-Nikon, Italy). 
 
3.15.2 Effect of Amiloride inhibitor on FITC- -conglutin  
HepG2 cells grown on glass coverslips were pretreated in DMEM (11.1 mM 
glucose) for 30 minutes with/without inhibitors of macropinocytosis (amiloride 
5mM). Then, cells were incubated with FITC--conglutin (50 mg/ml)  for 4 h at 
37°C in the continuous presence of inhibitors After cell fixation with PFM, the 
cells were washed with PBS pH 7.4 (Sigma) and permeablized with 0.1% Triton 
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X-100 (Sigma) in PBS for 20 minutes. The cells were washed and the nuclei 
labelled with 4′, 6′-Diamidino-2-Phenylindole (DAPI 1:20.000 in PBS) for 10 
minutes. After washing with PBS the coverslips were mounted in Vectashield 
mounting medium for fluorescence (Vector Laboratories) and subsequently, the 
cells were analyzed with confocal microscope.  
 
3.16 Mass spectrometry 
For mass spectrometry analysis, each 2D-gel spot was excised and destained in 
0.1% trifluoroacetic acid acetonitrile 1:1 (v/v) and dryed in a Speed Vac. Gel 
pieces were rehydrated with trypsin (sequence grade, Sigma Aldrich) solution (0.2 
g trypsin/spot in 50 L 50 M ammonium bicarbonate), and incubated overnight 
at 37°C. Peptides were extracted from the gel using 0.1% trifluoroacetic acid 
acetonitrile 1:1 (v/v). The material was dried, resuspended in 10 mL 0.1% v/v 
formic acid and desalted using Zip-Tip C18 (Millipore) before mass spectrometric 
(MS) analysis. Samples were separated by liquid chromatography using an 
UltiMate 3000 HPLC (Dionex, now Thermo Fisher Scientific). Buffer A was 0.1% 
v/v formic acid, 2% acetonitrile; buffer B was 0.1% formic acid in acetonitrile. 
Chromatography was performed using a PepMap C18 column (15 cm, 180 lm ID, 
3 lm resin, Dionex). The gradient was as follows: 5% buffer B (10 min), 5-40% B 
(60 min), 40-50% B (10 min), 95% B (5 min) at a flow rate of 0.3 lL/min. 
Mass spectrometry was performed using a LTQ-Orbitrap Velos (Thermo Fisher 
Scientific) equipped with a nanospray source (Proxeon Biosystems, now Thermo 
Fisher Scientific). Eluted peptides were directly electro-sprayed into the mass 
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spectrometer through a standard non-coated silica tip (New Objective, Woburn, 
MA, USA) using a spray voltage of 2.8 kV. The LTQ-Orbitrap was operated in 
positive mode in data-dependent acquisition mode to automatically alternate 
between a full scan (m/z 350–2000) in the Orbitrap and subsequent CID MS/MS 
in the linear ion trap of the 20 most intense peaks from full scan. Data acquisition 
was controlled by Xcalibur 2.0 and Tune 2.4 software (Thermo Fisher Scientific). 
Data Base searching was performed using the Sequest search engine contained in 
the Proteome Discoverer 1.1 software (Thermo Fisher Scientific). The following 
parameters were used: 10 ppm for MS and 0.5 Da for MS/MS tolerance, 
carbamidomethylation of Cys as fixed modification, Met oxidation and 
Ser/Thr/Tyr phosphorylation as variable modifications, trypsin (2 misses) as 
protease. 
 
3.17 Transmission electron microscopy (TEM) and immune-gold 
Labelling HepG2 cells, plated and grown on Transwell®, were incubated as above 
with/without 10-5 M -conglutin for 30 min, 3 and 24 h. Transwell membranes 
were washed with cold PBS and incubated for 1 h in PBS with 10 g/L heparin. 
Then, Transwell® membranes were fixed with 1.2% glutaraldehyde and 3.3% 
paraformaldehyde in 0.1 M PBS pH 7.4 at 4 °C for 3 h, dehydrated in an ethanol 
series and embedded in London Resin (Duranti, 1994). Immune-labelling was 
carried out on ultrathin sections at 4 °C overnight with an anti--conglutin 
polyclonal serum (1:100) and goat anti-rabbit antibody (1:20) conjugated with 20 
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nm gold particles. Ultrathin sections were stained with 2% uranyl acetate and lead 
citrate and examined with a JEOL 100SX TEM (Jeol Ltd., Tokyo, Japan).  
 
3.18 Homology 3D modelling 
-Conglutin 3D model was prepared by homology modelling using the programme 
ESyPred3D (http://www.unamur.be/sciences/biologie/urbm/bioinfo/esypred/) availed 
on line.  With the amino acid sequence sequence Q9FSH9_LUPAL and the 
soybean homologous protein, Bg7S, 3D structure as the template (PDB accession 
number: 3AUP). 
 
3.19 Western blotting 
Isoelectric focusing and -conglutin internalization and 
phosphorylation 
For IEF/SDS–PAGE analyses, cells were incubated with/ without 10-5 M -
conglutin for 6 h. At the end of incubation, cell medium was removed and the 
monolayers were incubated in PBS containing 10 g/L heparin for 1 h. After 
incubation HepG2 cells were lysed by a solution of 8 M urea, 2% CHAPS and 65 
mM 1,4- dithiothreitol (DTT) (Amersham Biosciences, Milan, Italy). The protein 
extracts were centrifuged at 10.000 xg for 30 min and immediately analysed or 
kept frozen at -80 °C until use. Isoelectric focusing (IEF) was performed on 7 cm 
pH 3-10 linear IPG strips (Amersham Biosciences, UK) following the procedure 
described by Capraro et al. (Capraro et al., 2008). The separation was performed 
on 9 cm X 7 cm 12% polyacrylamide SDS–PAGE gels using a mini-PROTEAN 
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III cell (Bio-Rad, Milan, Italy). The 2-D separations were repeated three times for 
each analytical set. The proteins in gels were transferred to 0.45 m-pore 
nitrocellulose membranes (Protran, Whatman, Dassel, Germany) by using the TE 
77 PWR Semidry Transfer Unit (Amersham Biosciences, UK), according to 
Towbin et al. -conglutin was immune-detected as already described (Magni et al., 
2005; Towbin et al., 1979).  
After blocking, membranes were then soaked in PBS buffer containing rabbit anti-
γ-conglutin (1:1500) and then with HRP-conjugate (1:2000). The labelled bands 
were detected with 0.6 g/l peroxidase (Bio-Rad) and hydrogen peroxide with 4-
chloro-1-naphthol (Sigma-Aldrich) as substrate. 
The antiserum to -conglutin was raised in rabbit using a non-glycosylated form 
of γ-conglutin in order to suppress potential carbohydrate unspecific binding, as 
described by Restani et al. (2005). The polyclonal antibodies were then immuno-
affinity purified as described by Casey (1979). This antibody preparation was used 
for all experiments carried out in this work.  
 
3.19.2 Insulin receptor pathway PI3K-AKT 
HepG2 cells were incubated with or without -conglutin 10-5M, Insulin 100 nM 
and Metfornin 10 mM in DMEM containing 11.1 or 30 mM Glucose for 6 or 24 
h. After incubation for indicated times cells were lysated  and the  cell pellet was 
treated with Nonidet P-40 (NP-40) lysis buffer [10 mmol/L Tris  Cl, pH 7.4, 10 
mmol/L NaCl, 3 mmol/L MgCl2 and 0.5% (v/v) NP40, containing a protease 
inhibitor cocktail]. Cells were separated into cytosolic and nuclear fractions by 
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centrifugation at 12,000 xg for 10 min. In the supernatants containing cytosolic 
protein concentrations were measured using BCA protein assay kit (Sigma-
Aldrich). Protein samples (20–50 µg prepared with the Laemmli method) were 
separated by 10 % SDS-PAGE and transferred to nitrocellulose membranes 
(Millipore, Bedford, MA). The membranes were blocked with 5% BSA in TBST 
(Tris-Buffered Saline and Tween 20) and probed overnight at 4 °C with anti Akt 
(Cell Signalling) 1:2000, anti Phospho-Akt Ser 473 (Cell Signalling) 1:2000, anti 
AMPK (Cell Signalling) 1:2000, anti Phospho-AMPK (Cell Signalling) 1:2000 
and anti β-actin (Sigma-Aldrich) 1:10000. After undergoing TBST washes, the 
membranes were incubated with peroxidase-conjugated secondary antibodies, and 
immunoreactive bands were visualized by enhanced chemiluminescence (BioRad 
ChemiDoc XRS). 
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7S ' experiment in cells cultures 
3.20 Cells cultures 
3.20.1 HepG2 cells  
HepG2 cells were grown in monolayers in 90 mm-diameter Petri dishes, and 
maintained at 37 °C in a humidified atmosphere of 95% air, 5% CO2 in minimum 
essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
nonessential amino acid solution (1%, v/v), penicillin (105 U/L), streptomycin (0.1 
g/L), tricine buffer (20 mM, pH 7.4), NaHCO3 (24 mM) and sodium pyruvate (0.11 
g/L). For experiments, cells were seeded in 35-mm plastic dishes (3-5 x 105 cells) 
and used just before reaching confluence.  
 
3.20.2 The 3T3-L1 preadipocytes  
The 3T3-L1 preadipocytes were seeded at 3x104 cell/well in 24-well plates and 
cultured in DMEM containing 1% sodium piruvate, 1% penicillin/streptomycin 
and 10% calf bovine serum (days 1 and 2). After reaching 100% confluence, the 
cells were differentiated in DMEM containing 1% sodium pyruvate, 1% 
penicillin/streptomicyn, 10% FBS, 0.5 mM isobuthylmethylxantine, 1 mM 
dexametasone and 1.7 mM insulin for 8 days, at which time >90% of cells were 
mature adipocytes with fat droplets (Martinez-Villaluenga et al., 2009). Cells were 
treated on day 8 of the differentiation process with 50 mM synthetic peptides 
dissolved in Dulbecco’s phosphate buffer saline. The incubation lasted 48 h at 
37°C in a 5% CO2 atmosphere.  
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3.20.3 Macrophages cell line RAW 264.7 
Macrophages cell line RAW 264.7 induced by LPS (1 mg/mL), were incubated for 
24 h in medium containing DMEM, 1% penicillin/streptomicyn, 1% sodium 
piruvate, and 10% FBS at 37°C in 5% CO2/95% air, in the presence of each peptide 
at 25 mM concentration.  
 
3.21 Cell viability  
Culture media from HepG2 cell lines exposed to synthetic peptides at different 
concentrations were tested by measuring the lactate dehydrogenase (LDH) 
activity, using a kinetic (LDH/LD) diagnostic kit (Sigma Diagnostics), essentially 
as previously described (Young, 1990) 
Adipocytes and macrophages viability was tested by using the CellTiter 96 
Aqueous One Solution Proliferation assay kit based on the novel tetrazolium 
compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4 
sulfophenyl)-2H-tetrazolium, inner salt (MTS), and an electron coupling reagent, 
phenazine ethosulfate (PES) (Promega Corporation, Madison, WI, USA) 
(Marshall et al., 1995). 
 
3.22 RT-PCR 
3.22.1 Lipid homeostasis evaluation  
For experiments designed to evaluate LDL-R, SREBP-2, PCSK9 and HMGCoA 
reductase mRNA expression, HepG2 cells were incubated for 6-8-16 h in MEM + 
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5% LPDS in the presence of 7S ’peptides (1 M and 10  M) or simvastatin (1 
M). Total RNA from HepG2 cells was isolated using RNeasy Mini Kit (Qiagen, 
Italy) according to the manufacturer’s instructions. All RNA samples were 
examined as to their concentration, purity and integrity based on the absorbance 
ratio at 260-280 nm and at 230-260 nm. Overall sample integrity was confirmed 
by agarose gel electrophoresis, showing sharp and intense 18S and 28S ribosomal 
RNA bands with the total absence of smears. In real time-PCR experiments five 
micrograms of total RNA from HepG2 was retrotranscripted with “iScript cDNA 
Synthesis Kit” (Bio-Rad Laboratories) according to the manufacturer´s 
instructions. RT-PCR assays were performed by the TaqMan technology on an 
ABI PRISM 7000 SDS (Applied Biosystems, Weiterstadt, Germany). Each PCR 
reaction contained 5 μL cDNA template, corresponding to approximately 50 ng of 
the total extracted RNA. We assessed LDL-R and 18 S (endogenous control) 
mRNA expression levels using the human LDL-R (Hs00181192_m1), and 18S 
(4319413E); HMGCoA red (hs00168352_m1), SREBP2 (hs00190237_m1) and 
PCSK9 (hs00845399_m1) Pre-Developed TaqMan Assay Reagents (Applied 
Biosystems). Results were compared to the values detected in untreated cells 
(arbitrary unit = 1). 
 
3.23 Oil Red O assay 
3.23.1 Lipid quantification in 3T3-L1 adipocytes  
Treated adipocytes were washed with cold Dulbecco’s phosphate buffer saline and 
fixed with 10% formaldehyde for 1 h. Then, cells were washed with 60% 
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isopropanol and let air-dried. Oil Red O stock solution (0.2 g in 60% isopropanol) 
was filtered through a 0.22 m membrane and added to lipid droplets for 10 min. 
After Oil Red O lipid staining, cells were washed with water four times and were 
air-dried. Oil Red O dye was eluted by adding 100% isopropanol after 10 min 
incubation at room temperature. Absorbance (A) at 510 nm of eluted isopropanol 
was measured using a microplate reader (Biotek Instruments, Winooksi, VA, 
USA). Inhibition of lipid accumulation in adipocytes was calculated using the 
following equation (Martinez-Villaluenga et al., 2009): 
% inhibition of lipid accumulation= (A control, 510 nm –A treatment, 510 nm)/A control, 510 nm 
x 100 
 
3.24 Fatty acid synthase (FAS) 
FAS activity was assayed by spectrophotometric method using a Sinergy 2 
Microplate Reader System equipped with a temperature controller (Biotek 
Instruments, Winooksi, VA, USA) as described (Martinez-Villaluenga et al., 
2010). NADPH oxidation was followed at 37°C by measuring the decrease in 
absorbance at 340 nm in a 96-well clear-bottomed polystirene plate (Corning, NY, 
USA). Reactions were performed in a final volume of 150 µL containing 3 µM 
acetyl-CoA, 10 µM malonyl-CoA and 35 µM NADPH and 0.3 µM FAS in 0.1 M 
potassium phosphate buffer. Initial rates were calculated for the slope of the 
progress curves during the first 5 min. Inhibition studies were performed by 
measuring the residual FAS activity after enzyme preincubation with peptides at 
different concentrations for 20 min at 37 ºC. 
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3.25 Oxygen radical absorbance (ORAC) assay. 
The ORAC assay was performed following Prior et al. (Prior et al., 2003) and 
Davalos et al. (Davalos et al., 2004) methods. Fluorescein reacted with free 
radicals generated by 2,2′-azobis(2-methylpropionamidine) dihydrochloride 
(AAPH) yielding a non-fluorescent product. Loss of fluorescence was measured 
over time in fluorescent microplate reader, (Biotek Instruments, Winooksi, VA, 
USA) at 37°C and sensitivity 60. Readings were made every minute at λexc 485 nm 
and λemi 520 nm. Then, the area under curve (AUC) was calculated as previously 
reported (Darmawan et al., 2010) and compared to a standard antioxidant, Trolox 
(vitamin E analogue). Results were expressed as µmol Trolox equivalents (TE)/ 
µmol peptide.  
 
3.26 Statistical analyses 
Data were expressed as means ± standard deviation or ± SEM of at least three 
replicates. Results were compared using one-way analysis of variance (ANOVA) 
followed by Dunnett’s test. P values < 0.05 were considered as statistically 
significant. 
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4. RESULTS 
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Results of Conglutin experiments  
 
4.1 Conglutin administration reduces plasma glucose in the “in vivo” model 
of type 2 diabetes 
The dosage of 28 mg/kg b.w. -conglutin was selected according to lowest dosage 
of the previous trials consisting of acute glucose overloads in normal rats (Magni 
et al., 2004). Body Weight were not modified either by glucose feeding or by -
conglutin treatment in all groups: controls, (244.6 ± 3.8) g; glucose-treated, (243.7 
± 5.5) g; glucose-treated + -conglutin, (241.00 ± 8.0) g. As depicted in Fig.1a, 
chronic glucose administration resulted in a statistically significant (p≤0.01) 
increase in fasting blood glucose (2.5 fold); conversely, simultaneous treatment 
with -conglutin attenuated the rise in glucose (1.9 fold) so that the glucose levels 
in these animals were reduced by 22% in comparison with those recorded in the 
glucose-treated rats.  
In glucose-drinking rats, insulin levels increased by 170% (2.7 fold) Fig. 1b; p≤ 
0.05); the treatment with -conglutin reduced this increase to 79% (p≤0.05), 
although the levels remained higher than in control animals. Chronic glucose 
feeding increased the IR index, as expressed by HOMA-IR, by 582% (Fig.1c; 
p≤0.05). -Conglutin treatment attenuated this increase by 252% in glucose-fed 
rats, and the comparison between the HOMA-IR indexes in the two groups of rats 
(glucose-treated and untreated) showed an improvement in IR by 48% (p≤0.05), 
following daily administration of -conglutin.  
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Figure 1: Effects of chronic glucose drinking, combined with or without -conglutin (-
C) supplementation (a) on plasma glucose levels expressed in mmol/l, (b) on plasma 
insulin levels expressed in ng/ml and (c) on index of insulin resistance (IR; plasma 
glucose x insulin/22.5= homeostasis model assessment (HOMA)). Values are means, 
with their standard errors represented by vertical bars, n 12. Mean values were 
significantly different from those of controls: * p≤0.05, ** p≤0.01. Mean values were 
significantly different from those of glucose group: †† p≤0.01. 
 
The oral glucose tolerance test, carried out at the end of experimental period on all 
animals enrolled in the study, showed (Fig. 2a) a statistically significant reduction 
upon 3-week treatment with -conglutin, both fasting blood glucose and 
postprandial blood glucose (2 h) were reduced (221 and 212 %, respectively; 
p≤0.05), suggesting improved insulin sensitivity in the treated animals (Fig. 2b). 
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Figure 2 b 
 
Figure 2:  (a) Influence of -conglutin (-C) supplementation on plasma glucose 
concentrations of rats during oral glucose overloading trials (2 g/kg b.w.). Plasma glucose 
was assayed in rats at various times from glucose overload as reported in the ‘Materials 
and methods’ section. (b) Fasting blood glucose (FBG) and 2 h postprandial blood 
glucose (PBG) determined during glucose overload experiment in the rats. Values are 
means, with their standard errors represented by vertical bars, n 12. ** Mean values were 
significantly different from those of controls (p≤0.01). † Mean values were significantly 
different from those of glucose group (p≤0.05).  
 
4.2 -Conglutin improved glucose metabolism “in vitro”  
Glucose consumption was examined in HepG2 cells following incubation with 
purified -conglutin. The dose of 10-5 M -conglutin was selected from previous 
experiments, where an up-regulation of LDL receptors was detected in HepG2 
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cells after pre-incubation with -conglutin (Sirtori et al., 2004). Cells were grown 
in DMEM containing different glucose concentrations in order to simulate normal 
(5.5 mM =99 mg/dl) or moderate high glucose (11.1 mM = 200 mg/dl) and severe 
hyperglycaemia (16.5 mM~300 mg/dl) in human subjects. Moreover, insulin (100 
nM and metformin (10 mM) were used alone or in combination with -conglutin 
to assess the potential synergism/antagonism in glucose consumption following 24 
or 48 h incubation. As depicted in Fig. 3, the addition of insulin or metformin to 
HepG2 cells grown in DMEM containing different amounts of glucose induced a 
statistically significant increase (p≤0.05) in the glucose consumption after 24 and 
48 h incubation. When the glucose in the culture medium was normal (5.5 mM), 
no statistically significant effect on glucose consumption was detected on the 
addition of -conglutin in all experimental conditions (control, insulin and 
metformin). On the other hand, the effect of -conglutin in glucose consumption 
(p≤0.05) was evident in cells grown in DMEM with moderate (11.1 mM) or 
elevated (16.5 mM) glucose content; moreover, the concomitant addition of -
conglutin to HepG2 cells exposed to insulin or metformin increased further the 
glucose consumption, normally stimulated by both compounds. In particular, when 
the glucose concentration in the culture medium increased from 5.5 to 11.1 mM, 
the glucose expenditure induced by -conglutin, after 24 h of incubation, was 
elevated to 100, 60 and 18 %, respectively in controls, insulin- and metformin-
treated cells (Fig. 3b). When the glucose concentration increased from 11.1 to 16.5 
mM, the amount of glucose consumed in 24 h was enhanced by 109, 33 and 43 %, 
respectively in controls, insulin- and metformin- treated cells by the addition of    
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-conglutin addition (Fig. 3c). This trend was shared by HepG2 cells incubated for 
48 h in the same experimental conditions: the addition of -conglutin induced a 
statistically significant increase in the amount of glucose consumed as depicted in 
the Fig. 3 (e and f). The glucose-lowering effect of -conglutin observed in HepG2 
cells was not linked to an increment in cell number, due to the glucose level, since 
we did not observe any change in methyltetrazolium salts optical density (data not 
shown) In addition, the results obtained following the exposure of HepG2 cells to 
-conglutin were compared for each time and glucose concentration with the 
respective controls. Moreover, a previous experiment (data not shown), in which 
mannitol was added to 5.5 mM glucose DMEM, pointed out that the present results 
were due to the activity of tested compounds (-conglutin, insulin and metformin) 
and not to the effect of hyperosmolarity. 
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Figure 3: Glucose consumption by HepG2 cells after 24 (panels A) and 48 h (panels B) 
growth at different glucose concentrations (1: 5.5 mM; 2: 11.1 mM and 3: 16.5 mM).  
The trials were: cells alone (control), treated with insulin (100 nM) or metformin (10 mM) 
in the absence (white bars) or presence (black bars) of 10 -5 M -conglutin. The tests were 
performed in DMEM supplemented with 0.2% BSA as detailed under Methods. Data are 
means + S.E.M. of 3 independent experiments, each performed in quadruplicate. * p≤0.05 
vs the -conglutin untreated trials. 
 
 
4.3 Flow cytometry glucose uptake assay 
The 2-NDBG uptake was examined in HepG2 cells following incubation with 
10 purified γ-conglutin. Insulin (100 nM) was used alone or in combination 
with γ-conglutin to assess the potential synergism/antagonism in glucose analogue 
uptake following 6 h incubation, as already observed in previous works  (Terruzzi 
et al., 2011).  
As shown in Figure 4, γ-conglutin alone or in combination with insulin stimulated, 
in a statistically significant way, the HepG2 cell glucose uptake by 64 % and 184 
%, respectively vs the untreated cells. Insulin alone increased glucose uptake by 
119%.  γ-Conglutin did not show any binding capacity toward glucose, as assessed 
by affinity chromatography and changes in refractometric indexes (Capraro 2011, 
unpublished results), therefore any direct involvement of the lupin protein in 
glucose transport into the cell could be ruled out. 
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Figure 4: Effect of γ-conglutin on basal and insulin-stimulated 2-NBDG uptake in HepG2 
cells. Cells were incubated in DMEM containing 11.1 mM glucose in the 
absence/presence of 2-NBDG (50 M) with and without 10-5 M γ-conglutin and 100 nM 
insulin for 6h. At the end of incubation cells were collected for the flow cytometry 
analysis. The relative fluorescence intensities minus the background levels were used for 
subsequent statistical analyses. Vertical bars show the mean ±SEM of three independent 
experiments, each performed in quadruplicate. Significant differences are marked by          
* p≤0.05 vs control cells, o p≤0.05 vs γ-conglutin treated cells and ☐ p≤0.05 vs insulin 
and γ-conglutin treated cells 
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4.4 Time course of -conglutin uptake by HepG2 cells as assessed by confocal 
microscopy using -conglutin antibodies 
The uptake of -conglutin by HepG2 cells, as monitored with  fluorescently- 
labelled -conglutin antibodies in confocal microscopy, is shown in Figure 5, 
thirty min after the treatment, it was already possible to observe some fluorescent 
spots around the cells (Fig. 5A), suggesting the presence of protein aggregates 
leaning against cell membranes. Whether these aggregates were only stacked 
outside the membrane or, at least in part, already inside the cells it was not clear at 
this time (Fig. 5A).  
Conversely, the intracellular uptake of some of these aggregates was more evident 
3 h later (Fig. 5B). A very different distribution pattern of fluorescence was 
observed at 6 h after the treatment, when the whole cytoplasm showed a diffuse 
and intense fluorescence, suggesting that -conglutin had spread in it, without a 
specific localization or aggregation in dense bodies. Some fluorescence spots were 
still visible at the cell border, possibly outside membranes. This scenario 
completely changed at 24 h, when the diffused cytoplasm fluorescence was much 
less intense and large brilliant spots were again visible at the cell periphery. At any 
considered time, nuclei were not labelled. 
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Figure 5: Immune-detection by confocal microscopy of HepG2 cells at different 
incubation times with -conglutin (red); nuclei are counterstained in blue by DAPI. 
Nuclei were not labelled at any considered time, as well as control cells without -
conglutin treatment (panel E). All bars = 20 m.  
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4.5 Two-D electrophoresis and mass spectrometry evidence of -conglutin 
internalisation and phosphorylation by HepG2 cells 
In order to confirm the intracellular uptake of lupin -conglutin by treated HepG2 
cells and monitor the status of the internalized protein, 2D IEF/SDS–PAGE of the 
cell lysates at 6 h incubation, when the cells showed a 64% increase of glucose 
uptake, was performed. The resulting 2D electrophoretic maps of the untreated 
control cells and cells after 6 h treatment with -conglutin are shown in Figure 6, 
panels A and A’, respectively. The two maps showed a very similar pattern. 
However, some spots, which were not present in the control sample, appeared in 
the -conglutin treated sample. These two positions in the electrophoretic map 
corresponded to that of -conglutin subunits (Magni et al., 2007), which consists 
of a main small subunit around 17 kDa and pI 6.2 and large ones of 30 kDa and pI 
8.7. For further evidence, the 2D maps of untreated and treated cells were blotted 
and revealed with anti--conglutin antibodies (Fig. 6 B and B’). With the 
untreated cells, no labelling was visible throughout the map, suggesting that no 
protein component of the cells cross-reacted with -conglutin antibodies. 
Conversely, in panel B’, two main spots around 30 kDa and other less distinct ones 
at 17 kDa were detected by the antibodies, thus confirming the presence of intact 
-conglutin subunits. Other unforeseen spots reacting with -conglutin antibodies 
were found in the blotted map (Fig. 6, panel B’) at the large subunit position, but 
with unusually low pIs. The acidic spots in the blotted map, indicated as spot 1 
(S1) and spot 2 (S2), as well as a main spot in the canonical position of -conglutin 
large subunit (S3), were excised, trypsin treated and submitted to MS/MS 
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spectrometry, as described under Methods. The results of mass analyses are 
detailed in Table 1. The analysis allowed to unequivocally identify the 3 spots as 
-conglutin, in agreement with the Western blot data. Moreover, the presence of 
phosphorylated amino acids was detected in various tryptic peptides of spots 1 and 
2, whilst none was seen in the unmodified -conglutin. The position of the 
phosphorylated amino acids in -conglutin sequence is shown in Table 1. The 
analysis of the predicted 3D structure of -conglutin confirmed the expected 
location of the modified amino acids at the surface of the molecule (not shown). 
However, due to the incompleteness of the sequence coverage, the presence of 
other phosphorylated amino acids could not be excluded 
 
 
Figure 6: Two-D electrophoretic maps of proteins from HepG2 cell lysates incubated for 
6 h in DMEM without (A) and in presence (A’) of the lupin seed protein -conglutin (10-
5 M). Figure B and B’, show antibody revelation of -conglutin in the blotted maps of 
S1 S2
 
 S1 
S3
 
 S1 
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cells incubated with (B’) or without (B) -conglutin. Reference -conglutin is also 
showed. In panel A’, the spots corresponding to the 30 kDa and 17 kDa -conglutin 
subunits were circled after identification by comparison to the reference map (see the 
white lupin 2D reference map on http://www.lupinproteinteam.unimi.it). These spots are 
not present in the untreated sample (panel A, dotted circles to locate the empty areas). 
Antibody revelation evidences the large (marked as Spot 3) and small subunits of -
conglutin in the treated sample (panel B’). Two acidic spots, revealed by the same 
antibodies, are marked Spot 1 and 2, respectively.  
 
a The residue position is referred to sequence Q9FSH9. 
 Table 1: List of phosphorylated peptides in 2D-gel spots S1, S2 and S3. 
 
4.6 Uptake and fate of -conglutin in HepG2 cells by TEM immune-labelling 
To shed light on the intracellular uptake pathway and the presence of -conglutin 
aggregates, TEM immune-localization of the protein at 30 min, 3 h and 24 h was 
performed. -Conglutin aggregation occurred around the numerous microvilli 
present on HepG2 cell membranes (Figure 7A and B), consistently with the above 
mentioned fluorescent spots leaning against cell membranes. These microvilli 
Sequence  Identified phosphorylated 
residue 
Position a Xcorr Charge m/z(Da) MH+ (Da) 
Spot S1       
HSIFEVFTQVFANNVPK T 36 1.58 3 686.33496 2056.99033 
RTPLMQVPVLLDLNGK T 298 1.74 3 625.34088 1874.00809 
KISGGVPSVDLIMDK S 327 1.87 4 410.46106 1638.82241 
AVGPFGLCYDTKK Y 321 1.43 2 768.34937 1535.69145 
SCSNLFDLNNP S 409 1.60 2 680.76617 1360.52507 
Spot S2       
RTPLMQVPVLLDLNGK T 36 2.07 3 625.33844 1874.00077 
KISGGVPSVDLIMDKSDVVW
R 
S 327 1.42 3 799.72986 2397.17502 
IPQFLFSCAPTFLTQK T 149 1.11 3 659.99481 1977.96988 
Spot S3       
Various peptides belonging to 
 -conglutin sequence 
No phosphorylated 
residues  
- - - - - 
95 
 
seemed to trap the protein, sometimes in large aggregates (Fig.7B). At 3 h 
treatment, some small aggregates were visible both stacked to the cell membrane 
(Fig.7C) or inside the cytoplasm (Fig.7D), with no clear signs of endocytosis, 
possibly because the lack of osmication during the fixation process prevented 
membrane visualization. Moreover, intense labelling was localized both in the 
protein aggregates stacked to microvilli and in some dense bodies in the cytoplasm 
(Fig. 7E). These bodies, being only labelled in some parts, were possibly formed 
by other substances, besides -conglutin, and corresponded to the brilliant 
fluorescent spots observed in the cytoplasm by confocal microscope at the same 
time course. Intriguingly, dense bodies were not present at 24 h, but the labelling 
was scattered in the cytoplasm, with rare aggregation (Fig. 7F). Serial sectioning 
showed that some of these protein aggregates were invaginated into the cell 
membrane, however still outside the cell (Fig. 7G). 
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 Figure 7: TEM ultrathin sections of HepG2 cells at 0 min (A), 30 min (B), 3 h (C-E) and 
24 h (F, G) incubation with-conglutin. -Conglutin is sometime localized in electron-
dense bodies (panel E, arrows) or scattered throughout the cytoplasm (panel E, 
arrowheads) and rare protein aggregates (P) are present. (G) Serial sectioning of an 
aggregate showing that its invagination into the cell membrane (arrow) (V, microvilli). 
ER, endoplasmic reticulum; M, mitochondrion. 
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4.7 Effect of endocytosis inhibitor on the cellular uptake of FITC--conglutin  
To clarify the mechanism of internalization of -conglutin into the HepG2 cells, 
inhibitory experiments of -conglutin cellular uptake were carried out using 
specific endocytosis inhibitor. The effect of the following endocytosis inhibitors 
on internalization of the protein were examined: filipin (5g/ml) and genistein 
(200 M) for caveolae/lipid raft mediated endocytosis, chlorpromazine (25 M), 
methyl--cyclodextrin (5 mM) for clathrin-mediated pathway and amiloride (5 
mM) for macropinocytosis. To study whether incubation with inhibitors of 
endocytosis would affect internalization of -conglutin, cells were preincubated 
for 30 minutes at 37 °C with inhibitors  and then, exposed  to FITC--conglutin 
(50 g/ml) for 4 h at 37°C in the presence of inhibitors (Figure 8). Treatment of 
the cells with amiloride significantly affect the FITC--conglutin internalization, 
with an approximately 69% decrease in the amount of cellular uptake. Treatment 
with filipin had no significant effect on -conglutin internalization. Methyl--
cyclodextrin, chlorpromazine and genistein showed a lower significant reduction 
in the internalization of protein (40%, 33% and 14% respectively). These results 
indicate that in HepG2 cells, the -conglutin was internalized preferentially 
through macropinocytosis pathway. 
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Figure 8: Effect of endocytosis inhibitors on FICT--conglutin uptake: HepG2 cells were 
pretreated for 30 minutes with or without inhibitors of caveolae/lipid raft-mediated 
endocytosis [filipin (5 g/ml) and genistein (200 M)], of clathrin-mediated pathway 
[chlorpromazine (25 M), methyl-b-cyclodextrin (5 mM) and of macropinocytosis 
[amiloride (5 mM)]. Then, cells were incubated with FITC--conglutin (50 g/ml) for 4 
h at 37°C in the presence of inhibitors. Subsequently, the cells were analyzed by FACS. 
*p < 0,05 vs controls, ** p <  0,01 vs controls. 
 
4.8 Effect of macropinocytosis inhibitor on FITC--conglutin internalization  
To confirm the potential role of macropinocytosis in the uptake of FICT--
conglutin, confocal microscopy study was carried out on HepG2 cells using 
amiloride (5 mM). As showed in Figure 9 after 4 h of incubation with -conglutin 
and in the absence of inhibitor, cytoplasm showed a diffuse and intense 
fluorescence due to the presence of FITC-protein. When cell were treated with 
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amiloride a very different distribution pattern of fluorescence was observed in 
panel C. FITC--conglutin was in fact visible at the cell border, outside 
membranes. This result confirmed the previous data, suggesting the 
macropinocytosis as main via of -conglutin internalization. 
  
 
 
 
 
 
 
 
 
 
Figure 9: Immune-detection by confocal microscopy of HepG2 cells at 4h incubation 
with FITC--conglutin (green); and with amiloride (5 mM) (panel C). Nuclei are 
counterstained in blue by DAPI, as well as control cells without -conglutin treatment 
(panel A). All bars = 20 m. 
 
 
 
4.9  -Conglutin: Involvement in PI3K-AKT insulin receptor pathway  
4.9.1 Effects of -conglutin on AMPK phosphorylation 
We monitored the ability of both insulin and -conglutin to stimulate the same 
signaling pathway in HepG2 cells. Insulin and Metformin, the first-line oral anti-
diabetic drug, was used as a positive control.  
To start the study of the potential effect of -conglutin on key proteins of the insulin 
signaling, AMPK, a sensor of energy status for maintaining cellular energy 
C 
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homeostasis (Hardie, 2011), was evaluated by analyzing the levels of  total and 
phosphorylated proteins in cell lysates by Western blot analysis. 
Figure 10 showed that the 24 h treatment with -conglutin, alone or in concomitant 
presence of insulin did not induce an increase in the levels of AMPK 
phosphorylated proteins. Metformin, as aspect, showed the high levels of the p-
AMPK/AMPK ratio.  
 
 
 
 
    Figure 10 A 
  
 
 
 
 
 
 
 
 
 
Figure 10 B  
Figure 10: Effect of -conglutin on phosphorylated 5’-AMP-activated protein kinase 
(AMPK) levels in HepG2 cells after 24 hour treatment. (A) Western blot analysis of 
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representative experiments. Equal loading of Western blots was ensured by -actin. (B) 
Values of p-AMPK/AMPK ratio relative to the control condition. (*) Indicate statistically 
significant differences (p≤ 0.05). 
 
4.9.2 Effects of -conglutin on AKT phosphorylation 
Akt, serine/threonine-specific protein kinase, is the molecular key in mediating the 
metabolic effects of insulin signaling. It lays downstream of PI3K and facilitates 
glucose uptake and glycogen synthesis in the liver (Whiteman et al., 2002). To test 
the modulation of Akt by -conglutin, phosphorylated and total Akt were evaluated 
in cell lysates by Western blot analysis after 6 and 24 hour incubation in DMEM 
containing 11.1 or 30 mM Glucose. Figure 11 A and B, show the results of cells 
treatment with -conglutin, insulin and metformin in the different experimental 
condition.  
After 6 h incubation in 11.1 mM Glucose DMEM , in cells treated with -conglutin 
we have a 5 fold increase in the phosphorylation of  Akt which goes up to 25 fold 
when cell were treated in concomitant presence of insulin. A similar rise in p- Akt 
value is present in all experimental conditions 
                      
 
 
 
 
 
Figure 11A 
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Figure 11B         
Figure 11: Effect of -conglutin on levels of phosphorylated and total Akt protein, in 
HepG2 cells, following 6 and 24 h incubation in DMEM with 11.1 or 30 mM glucose. 
(A) Bands of representative experiments. Equal loading of Western blots was ensured by 
* 
p
A
K
T/
A
K
T 
0
5
10
15
20
25
30
35
6 h
11.1 mM 30 mM
* 
0
2
4
6
8
10
12
14
16
24 h
11.1 mM 30 mM
* 
* 
* 
* 
CTR C-  Met Ins C-Ins 
CTR C- Met Ins C-Ins 
p
A
K
T/
A
K
T 
Glucose 
Glucose 
103 
 
-actin. (B) Data of p-Akt/Akt ratio; values are expressed as relative to the control 
condition and are means ± SD* (p ≤0.05). 
 
A different pattern was observed in HepG2 cells after 24 h of incubation in 11.1 
mM DMEM where in presence of -conglutin was observed a decrease in the 
phosphorylated form of protein. Because is now that PI3K is involved in Akt 
activation, in order to confirm the role of PI3K/Akt pathway in the effect of -
conglutin the cells were expose to a selective inhibitor of PI3K/Akt 
(LY294002) and the levels of Akt and its phosphorylated form were assayed and 
compared with the values recorded in cells incubated in the absence of inhibitor. 
In figure 12 (A/B) data show that LY294002 treatment decreased p-Akt levels 
in all experimental condition (6 or 24 h incubation)  whereas the increased ratio of 
p-Akt/Akt were recovered in HepG2 cells in the presence of -conglutin alone or 
in the  concomitant presence of insulin  when cells are not exposed to LY294002 
vs values detected in control groups. However, neither LY294002 than -
conglutin, significantly affected the levels of total Akt indicating that the inhibition 
in phosphorylation at Ser-473 Akt was not due to a nonspecific effect.  
This data, suggest that PI3K/AKT pathways may be involved in the glucose 
homeostasis effect induced by -conglutin-induced effects. 
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 Figure 12 A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 B 
 
Figure 12: Effect of-conglutin and selective inhibitor LY294002 (LY) on total Akt and 
p-Akt levels in HepG2 cells. Cells were incubated in the presence or absence of 20 M 
LY for 1 h and later with 10-5M -conglutin or 100 nM Insulin for 6 or 24 h. (B) Data of 
p-Akt/Akt and (A) Bands of representative experiments. * indicate statistically significant 
differences (p ≤ 0.05). 
 
 
 
 
 
*
 
*
 
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
5
p
A
k
t/
A
k
t
6H 24 H + LY294002
CTR -C -C + Ins Ins
*
 
*
 
105 
 
Results of  ’ 7S soy protein experiments 
 
4.10 Body weight and food consumption in animal treated with ’ 7S 
subunit 
At the end of the experimental period (four week) the oral administration of IDN 
6442 (7S’enriched), IDN 6443 (’E) (Supplied by INDENA, Scientific 
department Milano, Italy), and clofibrate, in rats maintained on a 
hypercholesterolemic diet, or feed on standard diet, body weight and food intake 
was comparable with that of the untreated rats. Table 2 shows that in fact the 
increase () of body weight recorded at the end of treatment was similar in the 
different groups, both treated and non-treated rats with the test compounds, 
indicating that the amounts of recombinant polypeptide (’E) used in this 
experiment did not affect either the normal process of growth of the animals 
neither on the food consumption that was equal to 14.6 gr/day for rats fed in 
hypercholesterolemic diet. This value, due to the higher caloric content of the diet 
itself, is lower than that of the rats fed with on standard diet (20 gr/day). 
 
4.11 Plasma levels of total cholesterol, triglycerides and blood glucose of 
hypercholesterolemic rats 
It can be observed that the hypercholesterolemic diet is able to induce a statistically 
significant increase, (p≤0.001), in the levels of total cholesterol, plasma 
triglycerides, and glucose compared to the values found in animals fed the standard 
diet (Table 3). In particular, plasma cholesterol and triglycerides levels increased 
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by 399 and 70% respectively in rats fed HC diet respect to the rats fed standard 
diet at the end of the treatment. The oral treatment with proteins under 
investigation caused a statistically significant reduction in the cholesterol and 
triglyceride levels compared to the values found in untreated animals (* p≤0.05, 
** p≤0.001). 
 
 
Table 2: Effect of administration of IDN 6443, IDN 6442 and clofibrate on the 
performance of body weight in rats fed on hypercholesterolemic diet. p≤ 0.05 vs 
standard diet. 
 
As show in Table 3 as show that, IDN 6442 (7S-' rich), administered at a dose 
of 20 mg / kg b.w (around to 15.42 mg of 7S protein enriched in ’ subunit which 
correspond to 5.53 mg/kg b.w. of protein of ' subunit) induced a reduction in the 
levels of cholesterol and triglycerides (-27% and -34%, respectively) comparable 
to that previously published (Duranti et al., 2004).  IDN 6443 ( 'E), was used at 
concentrations of 25 mg/kg b.w. (5.65 mg protein /Kg b.w.) and 50 mg /Kg b.w. 
Group Body weight gr  Food intake 
 Pre Post gr gr/day 
Standard diet 160±2 341±12 181±11 20±0.8 
HC diet 151±3 326±10 175±9 14±0.9 
+IDN 6442 (20 mg/Kg) 153±2 331±7 178±7 14±1.0 
+IDN 6443 (25 mg/Kg) 148±2 350±7 201±7 15±0.8 
+IDN 6443 (50 mg/Kg) 154±2 334±7 180±6 15±1.2 
+ Clofibrate (200 mg/Kg) 152±2 321±6 169±7 15±0.9 
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(11.3 mg protein /kg b.w.), and although the concentration of active principle is 
minimal compared to the amount of product administered, is characterized by a 
remarkable reduction activity of both total cholesterol (-29 and 26%, respectively 
with 25 and 50 mg/kg b.w.) and  triglycerides (-13 and - 23%, respectively with 
25 and 50 mg/kg b.w.).  The lipid-lowering effect is comparable to that observed 
in rats treated with 200 mg/kg of clofibrate, as a reference drug. No statistically 
significant change in plasma glucose levels were induced by the treatment with the 
test compounds. 
 
    
 Cholesterol Triglycerides Glucose 
 mmol/L mmol/L mmol/L 
    
 
Standard diet 1.19±0.09 0.71±0.05 4.95±0.1 
    
HC diet 5.94±0.16    1.21±0.06 6.43±0.67 
    
+ IDN 6442 (20 mg/Kg) 4.34±0.16**      0.80±0.07* 5.21±0.56 
    
+ IDN 6443 (25 mg/Kg) 4.24±0.15**  1.05±0.04** 6.63±0.42 
    
+ IDN 6443 (50 mg/Kg) 4.39±0.27** 0.93±0.06** 6.07±0.14 
      
 + Clofibrate (200 mg/Kg) 4.06±0.26**   0.79±0.11*  6.36±0.44 
 
Table 3: Concentrations of total cholesterol and triglyceride in plasma rats fed HC diet 
for 28 day treated or untreated   IDN 6442, IDN 6443 and clofibrate respectively. Doses 
(20; 25, 50; 200) are mg of product administered for (kg body weight for day). Values 
are means ± SEM, n = 9 rats. *p≤0.05, **p≤0.01 versus HC rats.  
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4.12 Serum lipid and lipoprotein concentrations 
In rats fed with standard diet, cholesterol is mainly carried (about 63%) by the 
high-density lipoprotein (HDL). The switch to hypercholesterolemic diet, is 
characterized by an evident increase in the concentration of cholesterol and 
triglycerides parallel by a marked increase (values ranging between 61 and 77% in 
relation to the treatment) in the concentration of lipoproteins of density less than 
<1.006 gr/ml (VLDL) that become the main transporter of cholesterol with a 
decrease in HDL fraction. 
 
  
 
Hypercholesterolemic diet 
 
Standard 
Diet 
Control 
 IDN 6442 
20 mg/Kg  
IDN 6443 
25 mg/Kg 
 IDN 6443 
50 mg/Kg 
Clofibrate 
200 mg/Kg  
cholesterol  
mmol/L       
Total 1.19±0.09 5.94±0.16 4.34±0.16** 4.24±0.15** 4.39±0.27** 4.06±0.26** 
VLDL 0.33±0.01 4.10±0.31 2.63±0.15** 2.80±0.13** 2.73±0.08** 3.10±0.09** 
LDL 0.12±0.01 0.39±0.05 0.29±0.03* 0.24±0.02* 0.25±0.04* 0.08±0.01** 
HDL 0.75±0.02 1.45±0.08 1.42±0.08 1.22±0.09* 1.43±0.05 0.85±0.04** 
AI  0.6±0.01 3.01±014 2.05±0.08 2.49±0.08 2.08±0.05 3.74±0.04 
triglycerides  
mmol/L       
Total 0.71±0.05 1.21±0.06 0.80±0.07** 1.05±0.04* 0.93±0.06** 0.79±0.11** 
VLDL 0.67±0.02 1.15±0.06 0.72±0.07** 0.99±0.04* 0.88±0.04** 0.75±0.04** 
LDL 0.04±0.00 0.04±0.00 0.03±0.00 0.04±0.00 0.03±0.00* 0.02±0.00** 
HDL 0.01±0.00 0.03±0.01 0.04±0.01 0.02±0.01 0.02±0.00** 0.01±0.00** 
 
Table 4: Plasma total cholesterol and triglycerides and their distribution in the separated 
lipoproteins of rats fed on a standard or the hypercholesterolemic diet with or without 
treatment with IDN 6442, IDN 6443 and Clofibrate. AI (atherogenic risk index, 
estimated in term of VLDL-chol + LDL-chol to HDL-chol ratio).  Values are means 
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+ SEM of 9 rats per group for plasma total cholesterol and triglycerides. The cholesterol 
and triglycerides in the different lipoproteins are from 3 pools of 3 animals per group. 
Value are means of 3 replicate.*p≤0.05, **p≤0.001 vs control. 
 
 
The treatment with the different products (IDN 6442, IDN 6443 and clofibrate), at 
the concentrations tested in this study, leads to a statistically significant reduction 
(p≤0.001, p≤0.05) in the amount of cholesterol carried by VLDL with little 
variation in that transported by LDL and HDL, when compared with values 
detected in hypercholesterolemic untreated rats (Table 4). Moreover, it is worth to 
note that the treatment with the different products based on soy proteins are able 
to reduce markedly the atherogenic risk index, estimated in term of VLDL-chol + 
LDL-chol to HDL-chol ratio, compared to that of rats fed on HC diet. In rats 
treated with 7S '-rich or the ' E polypeptides at different doses (25 and 50 mg/Kg 
b.w.), the index was, in fact, reduced by 54, 43 and 52 %, respectively (Table 4). It 
should however be noted that the 7S soybean polypeptides administration did not 
induce  a return to the lipid distribution in the various lipoprotein classes as showed 
in Table 5, in which the data are expressed not as an absolute value (mg/dl) but as 
a percentage. The same trend is observable as regards the transport of triglycerides 
by the different lipoprotein fractions in hypercholesterolemic rats. 
 
 
 
 
110 
 
  Hypercholesterolemic Diet   
 
Standard diet Veicolo 
+ IDN 6442 
20 mg/Kg 
+ IDN 6443 
25 mg/Kg 
+ IDN 6443 
50 mg/Kg 
+ Clofibrate 
200 mg/Kg  
COL 
(mmol/L)       
       
Total 1.19±0.09 5.94±0.16 4.34±0.16** 4.24±0.15** 4.39±0.27** 4.06±0.26** 
%VLDL 27.8 68.4 60.6 65.7 62.0 76.7 
%LDL 10.1 6.7 6.7 5.5 9.5 2.0 
%HDL 60.5 24.8 32.7 28.7 32.4 21.2 
       
TG  
(mmol/L)       
       
Total 63±4.6 107±5.5 71±6.2** 93±3.3* 82±5.2** 70±9.8** 
%VLDL 92.4 95.0 88.4 93.7 94.7 95.8 
%LDL 6.5 2.9 4.5 3.9 3.1 2.3 
%HDL 1.9 2.3 6.1 2.4 2.2 1.8 
 
Table 5: Effect of administration of IDN 6442 and IDN 6443 on the distribution of 
lipoproteins cholesterol and triglycerides (percentage) in rats on a hypercholesterolemic 
diet. Data are expressed as mean ± S.E.M. of 9 rats per group. Treatment: 28 days. 
Significance between the different groups of animals in hypercholesterolemic diet:             
** p≤0.001 vs vehicle.  
 
 
4.13 Liver lipids  
As expected, the administration of the Nath’s hypercholesterolemic diet induced a 
significant increase (approximately 2-fold) of the liver weight, together with a 
parallel increase in levels of free and esterified cholesterol, compared to animals 
feed with the standard diet. The free/esterified ratio was 9-fold lower in HC 
animals (Table 6). However, no treatment with the test substance (IDN 6442: 7S 
' enriched; IDN 6443' extension and  clofibrate) was able to induce a substantial 
change in terms of statistically significant differences compared to the value 
detected in untreated hypercholesterolemic rats either as lipid content (total 
cholesterol and triglycerides) or as a distribution (free and esterified cholesterol). 
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The only statistically significant difference observed was related to the lower 
content of esterified cholesterol in the groups treated with IDN 6442 and clofibrate. 
This trend is confirmed if it is taken into account the overall content of esterified 
cholesterol in the liver. It can be observed, in fact, that the treatment with IDN  
6422 (E.C. 178 total mmoles p≤0.05) and with clofibrate (E.C. 171 total mmoles, 
p≤0.05) have been able to induce a statistically significant reduction of the 
esterified cholesterol to the hypercholesterolemic control group (E.C. 227 total 
mmoles). Regarding the total content of triglycerides in the liver it can be observed 
that the treatment with clofibrate was able to induce a clear reduction of liver 
triglycerides contenent (from 470 total mmoles in hypercholesterolemic vs 323 
total mmoles in clofibrate treated rats); this reduction is also found when the data 
are expressed as mmoles of triglyceride per gram of liver tissue. The treatment 
with IDN 6422 and IDN 6443 did not lead to a statistically significant variation of 
the content in hepatic triglycerides compared to the values found in 
hypercholesterolemic controls. 
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Table 6: Data are expressed as mean ± SEM of three pool for 9 rats in the group. Each 
analysis was carried out in triplicate. * p ≤0.05, ** p ≤0.001 vs vehicle. 
 
 
4.14 Evaluation of the LDL receptor expression by RT-PCR  
The treatment with ’E-polypeptides has induced an increased expression of 
the mRNA of LDL receptor (LDL-R) compared to that recorded in animals fed on 
hypercholesterolemic diet and treated with vehicle alone, as show in Figure 13. In 
particular, the administration of IDN 6442 and IDN 6443 at the highest 
concentration (50 mg/kg b.w.), induced an increased expression of the mRNA of 
LDL-R (+1.7 fold) compared to values recorded in control group. The compound 
IDN 6443, at a concentration of 25 mg/kg body weight, resulted in a 1.8-fold 
increase, whereas the treatment with clofibrate induced a 2 fold increase in the 
  
Standard 
diet  
HC  diet 
 
 Control IDN 6442 IDN 6443 clofibrate 
 
 
 
 
20 
mg/kg 
    25 mg/kg 50 mg/kg 200 mg/kg 
Body weight, 
g 
341±12 326±10 331±7 350±7 334±7 321±6 
Liver weight, 
g 
9.53±0.68 18.90±1.38 17.41±0.67 21.62±2.16 18.41±0.94 19.26±1.23 
FC, mmol/g 3.98±0.18 5.92±0.31 6.36±0.44 4.50±0.36 5.61±0.31 9.41±0.08 
EC, mmol/g 0.87±0.09 11.99±0.28 10.20±0.12* 12.99±1.41 16.03±0.18 8.86±0.14* 
FC/EC mmol/ 
mmol 
4.57 0.49 0.62 0.35 0.35 1.06 
TG, mmol/g 7.25±0.77 24.88+1.90 29.74±1.37 35.54±1.29 28.29±1.92 16.82±1.63** 
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expression of mRNA of LDL-R compared to those observed in the 
hypercholesterolemic control group. 
 
 
                                           
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 13: Effect of the administration of the peptides IDN6442 (20 mg/Kg), IDN6443 
(25 and 50 mg/kg) and clofibrate (200 mg/kg), in hypercholesterolemic rats, the mRNA 
expression of the LDL receptor compared to the HC control treated with CMC. Data are 
expressed as mean ± S.E.M. (pool n. 3) relative to 9 rats per group. Each analysis was 
conducted in triplicate. Significance between the different groups of animals fed on 
hypercholesterolemic diet: ** p≤0.001 vs vehicle.  
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Synthetic peptides from soy 
 
4.15 Effect of synthetic peptides on lipid homeostasis in HepG2 cells 
Sterol response element-binding protein SREBP-2 preferentially regulates genes 
involved in cholesterol homeostasis by activating the transcription of 5-hydroxy-
3-methylglutaryl-coenzyme A reductase (HMGCoA Red) and low density 
lipoprotein receptor (LDL-R) (Brown and Goldstein, 1997). The results obtained 
in the present study pointed out that some of peptides, belonging to ’,  and  
subunits of 7S soy globulin, when exposed to HepG2 cells displayed different 
effect on the expression of LDL-R, SREBP-2 and HMGCoA red mRNAs, as 
recorded by real time PCR. As expected (Figure 14) simvastatin induced a marked 
increase of LDL-R (+1.5 fold), SREBP-2 (+1 fold) and a marked decrease of 
HMGCoA red (-60%) vs untreated cells. Peptide C (RKQEEDEDEEQQREE) and 
E (KNPQLR) tested at 1 M concentration displayed increased expression of 
mRNA LDL-R (+2.3, and +1.9 fold), SREBP-2 (+1.8, and +3.3 fold) and a 
decreased expression of mRNA HMGCoA red (-30, and -70 %, respectively) vs 
values detected in untreated cells (arbitrary unit = 1). This trend was similar to that 
observed in HepG2 cells treated with 1 M simvastatin. Peptide D showed similar 
behavior at higher concentration (10 M); increased expression of mRNA LDL-R 
(+0.5 fold), SREBP-2 (+2 fold) vs untreated HepG2 cells have been detected. 
Although the amino acid sequences of peptides A and B are present in ’ extension 
(’E) polypeptide they were ineffective, at both tested concentrations, on LDL-R 
and SREBP-2 mRNA expression; although an inhibition of HMGCoA red 
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expression was observed. This result could suggest that these amino acid 
sequences are not completely involved in the lipid lowering mechanism.  
 
 
 
 
Figure 14 
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Figure 14: Effect of synthetic peptides on the expression of LDL-R, SREBP-2, and 
HMGCoA red mRNAs by RT-PCR. HepG2 cells were incubated for 16 h in MEM + 5% 
LPDS in the presence of each peptide (1 and 10 M) or simvastatin (1 M). Results were 
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compared to the values recorded in untreated cells (arbitrary unit=1, red line). Values are 
the mean +S.D. of three independent triplicates. Abbreviation: S=simvastatin.                       
** p<0.005; *p<0.05 vs negative control (untreated cells) 
 
 
 
4.16 Effect of synthetic peptides from -conglycinin on lipid accumulation, 
FAS activity and anti-oxidant activity in 3T3-L1 adipocytes 
Table 7 presents the percentage inhibition of lipid accumulation in 3T3-L1 
adipocytes after 48 h of treatment with 50 M peptides compared to their controls. 
Treatment with synthetic peptides from -conglycinin decreased lipid 
accumulation in the adipocytes from 12 to 27 % compared to negative controls 
(untreated cells). All synthetic peptides were potent inhibitors of FAS activity. In 
particular, the large peptide C (RKQEEDEDEEQQRE) resulted the most active 
compound to reduce lipid content. It was shown, in fact, a higher inhibitory effect 
(-27% vs untreated cells) on lipid accumulation and a significantly higher (p< 0.05) 
potency (IC50= 16 mM) on FAS inhibitory response compared to the other peptides 
under study. Moreover, peptides B (QKEEEKHEWQ) and D (EITPEKNPQLR) 
showed decreased lipid accumulation (18 and 19%, respectively) and the same 
potency (26 and 25 M, respectively). Peptides A (SEEEEEDQ) and E 
(KNPQLR) were characterized by higher IC50 and lower inhibition of lipid 
accumulation in comparison with the other peptides tested. These results confirm 
previous data where the FAS inhibitory potency of soy peptides also correlated 
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with their molecular mass; in addition the large inhibitory peptide 
(RKQEEDEDEEQQRE) bond to thioesterase domain of human FAS blocking the 
active site of such domain, as predicted by molecular docking (Martinez-
Villaluenga et al., 2010). The ORAC assay is widely used to determine antioxidant 
capacity (AC) “in vitro”  by measuring the scavenging activity of peroxyl or 
hydroxyl radicals (Davalos et al., 2004) . The amino acid sequence of peptides 
tested belong to ’,and  subunit of -conglycinin none of them showed a 
significant anti-oxidant capacity, since the results obtained varied between 11 and 
15 mol Trolox equivalent/mmol peptide (Table 7).  
 
 
Peptide % inhibition 
of lipid accumulation 
FAS activity 
IC50 (M) 
AC 
 
A 12 + 1.3* 56* 11 
B 18 + 2.0* 26* 15 
C 27 + 3.2** 16** 11 
D 19 + 3.1* 25* 13 
E 14 + 1.8* 73* 13 
 
Table 7: Antioxidant activity and inhibitory effect of synthetic peptides (50 mM) on lipid 
accumulation in 3T3-L1 adipocytes after 48 h and on fatty acid synthase (FAS) activity. 
AC= anti-oxidant capacity (mol Trolox equivalents/mmol peptide). Values are the mean 
+ S.D. of three independent triplicates. ** p<0.005; *p<0.05 vs negative control 
(untreated cells). 
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4.17 Effect of synthetic peptides on inflammation markers in RAW 264.7 
cells 
It is known that inflammation is part of the defense mechanism against infectious 
agents and injury. We studied the effect of each peptide (25 M concentration) on 
the protein expression of iNOS in macrophages using Western blot. Table 8 shows 
that the expression of iNOS was differently affected by synthetic peptides. 
Western blot analyses (data not shown) pointed out the protein expression of iNOS 
was barely detected in the non-stimulated cells. However, the level increased 
markedly after 24 h of LPS treatment. Peptide A (SEEEEEDQ), B 
(QKEEEKHEWQ), and E (KNPQLR) reduced the expression of iNOS by -71,        
-75 and -44%, respectively. COX-2 appears to be the dominant source of 
prostaglandin formation in inflammation, although its role in the reduction of 
inflammation was indicated in COX-2 Knock Out mice. To evaluate the role of 
synthetic peptides in inflammation, expression of COX-2 in LPS-stimulated RAW 
264.7 cells was measured. As indicated in Table 8, COX-2 expression was 
markedly reduced by peptide A, B, and E by 54, 34, and 79 %, respectively. 
Peptide C (RKQEEDEDEEQQRE), and peptide D (EITPEKNPQLR) showed 
lower inhibitory activity on both inflammation markers. These data support 
previous results indicating that peptides released by “in vitro” or “in vivo” 
enzymatic digestion from different protein components present in the soybean seed 
are characterized by different physiological functions.  
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Peptide % inhibition of iNOS  % inhibition of COX-2 
A 71 + 3.8** 54 + 1.6 ** 
B 75 + 2.1 ** 34 + 2.5 ** 
C                   43 + 2.9 * 20 + 1.7 * 
D 25 + 1.7 * 25 + 2.3 * 
E 44 + 2.8 ** 79 + 3.6 ** 
 
Table 8: Effect of synthetic peptides (25 mM) on pro-inflammatory responses in LPS-
induced RAW 264.7 macrophages after 24 h. Values are the mean + S.D. of three 
independent triplicates. ** p<0.005; *p<0.05 vs negative control (untreated cells). 
 
  
4.18 Effect on plasma lipids and LDL receptor expression of the “in vivo”  
        treatment with synthetic peptide (NPDNDE)   
Total cholesterol and triglyceride were analysed at the end of 21 days of treatment 
with NPDNDE (5 mg/Kg b.w. /day), results are shows in Figure 15. The data were 
compared with that obtained in rats treated either with whole ’ (20 mg/Kg b.w.) 
or clofibrate (200 mg/Kg b.w.), as reference drug. The oral administration of 
NPDNDE peptide resulted in lower plasma lipid level, cholesterol (-37%, 
triglycerides, -38%) vs value recorded in rats fed casein-cholesterol diet alone. 
Four-fold amount of ’ chain reduce cholesterol and triglyceride by 37 and 25% 
respectively. Similar results were obtained in clofibrate-treated rats. Moreover, 
synthetic peptide increased the expression of mRNA LDL-R (+53 %) (Fig 15 B), 
thus restoring receptor activity suppressed by HC diet.  
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Figure 15 C 
Fig 15: (A) Plasma lipid levels, cholesterol and triglycerides in HC fed rats after 21 days 
oral administration of NPDNDE peptide. (B) Expression of LDL-R mRNA in liver of HC 
rats treated with NPDNDE peptide. Results were compared to the values detected in 
untreated rats (arbitrary unit = 1) *p<0.05 vs control. 
 
 
4.19 Modulation of SREBP-2, LDL-receptor, and PCSK9 mRNA expression  
in HEPG2 by NPDNDE peptide 
To evaluate the potential effect of NPDNDE peptide on the modulation of LDL-
R, SREBP-2 and PCSCK9, HepG2 cells were incubated for 6, 8 and 16 h in MEM 
+5% LPDS w/wo whole ’ subunit (3.5 M), or synthetic peptide (10-5 M), or 
simvastatin (1 M), as a positive control. At the end of incubation, cells were 
processed for LDL-R, SREBP2 and PCSK9 mRNAs by RT-PCR. Increased 
mRNA expression of LDL-R at 6h by + 2.5 fold (for both substances) (Figure 16 
A), for SREBP2 (8h: +1.5, +1.2 fold), and PCSK9 (8h: +3,5; +1.5 fold) were 
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detected in cells exposed to NPDNDE, respectively vs ’and simvastatin exposed 
cells (Fig. 16 B-C). 
 
Figure 16 A 
Figure 16 B 
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Figure 16 C 
Fig.16: Effect of NPDNDE peptide on the expression of LDL-R, SREBP-2 and PCSK9 
mRNA by RT-PCR. HepG2 were incubated with 3.5 M ’7S subunit or synthetic 
peptide (10-5 M). Results were compared to the values recorded in untreated cells 
(arbitrary unit =1). Values are the mean ± S.D. of three independent triplicates. * p≤0,05; 
**p≤0,005 vs negative control. 
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5. DISCUSSION AND CONLUSION   
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Type 2 diabetes is a chronic metabolic disorder, often characterized by Insulin 
resistance, which leads to several secondary complications, including 
hypertension, atherosclerosis, coronary artery disease and hyperlipidemia (King et 
al., 1998). Approximately 150 million people worldwide are affected by the 
disease at present, with a projection of 300 million people being affected by 2025. 
Diabetes has become a serious public health problem, particularly in developed 
countries (Parikh et al., 2007). Research in an effective anti-diabetic agent, in 
addition to those already available, would be of great interest for the treatment of 
type 2 diabetes. Legume seeds, due to the nutraceutical potentialities of some of 
its proteins, may provide an alternative to the usual treatment of glucose 
metabolism disorders. Specifically, lupin flours, such as other pulses, are 
characterized by a low glycaemic index, so they can be useful in the prevention of 
IR in human subjects (Duranti, 2006).  
Lupin seeds are characterized by a high content of protein, about 35%, and by low 
levels of isoflavones and anti-nutritional factors (Champ, 2001). The anti-diabetic 
activity of toasted lupin seeds was initially described, in the middle of the last 
century, by Ferranini & Pirolli (Ferranini, 1937) and by Orestano (Orestano, 1940), 
who proposed lupin as a substitute for the insulin therapy in mild-to-medium 
diabetes mellitus, but no further studies have been carried out to identify the 
molecule responsible of this biological effect.  A few years ago the isolated lupin 
protein was found to bind insulin in vitro, by using both affinity chromatography 
on an insulin-bound matrix and Surface Plasmon Resonance (SPR). In parallel, 
suitable amounts of isolated protein were tested in glucose overloading trials on 
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rats. The results, reported in a significant decrease of the under-curve area of time 
course of glycaemic concentration with an effect similar to that of metformin at 
about half the dose of the lupin protein (Magni et al., 2004). Studies on both the 
biological activity of lupin γ-conglutin and its metabolic effects are currently 
ongoing. 
In the attempt of identifying the active principle responsible of the glucose 
controlling capacity attributed to a lupin seed component, a study on a specific 
lupin protein, named conglutin γ, was initiated. -Conglutin was considered a good 
candidate on the basis of previous finding that an homologous soybean seed 
protein, named Bg7S, was found to display a binding capacity to some small 
regulatory proteins, including insulin (Hanada and Hirano, 2004). However, these 
precursor studies primarily focused on the modalities and possible physiological 
role of the interaction between the soybean protein and an endogenous regulatory 
peptide, thus neglecting the potential effect(s) of the soybean protein on the human 
body carbohydrate metabolism. Due to the amino acid sequence similarity (63%) 
between soybean Bg7S (SwissProt Database accession number: P13917) and lupin 
γ-conglutin (SwissProt Database accession number: Q9FSH9), a molecular and 
metabolic study on the latter protein was recently undertaken. 
In this work we have studied the potential effect of -conglutin treatment glucose 
lowering effect in “in vivo” and “in vitro” models, monitor the protein 
internalization in cells and studied the interference whit the insulin receptor 
pathway.  
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In the first study, the addition of 10% glucose in drinking water induced 
hyperglycaemia and hyperinsulinaemia in rats similar to that observed in human 
subjects. No side effects have been detected during the experimental period, such 
as those recorded in animals undergoing streptozotocin (Dabros et al., 2004) or 
alloxan (Pari and Saravanan, 2002) treatment to mimic diabetes. -Conglutin 
administration has been demonstrated to counteract the plasma glucose increase as 
well as to improve the insulin sensitivity, normally reduced by the glucose rich 
drinking-water. In the -conglutin treated rats, the insulin sensitization was 
increased significantly, as indicated by the 48% reduction in the homeostasis 
model of insulin resistance. It is worth noting that the hypoglycaemic effect in vivo 
was obtained by the use of a preparation, which contained a -conglutin amount 
corresponding to the lowest dose previously used in acute trials of glucose 
overload (Magni et al., 2004). Moreover, lower glucose levels were detected in -
conglutin treated rats following oral glucose overload; these results were 
confirmed by lower glycaemia in fasting and two hours postprandial conditions. 
Recently, Terruzzi et al. (Terruzzi et al., 2011) have demonstrated that -conglutin 
may regulate muscle energy metabolism, protein synthesis and major 
histocompatibility complex gene transcription through the modulation of insulin 
signaling pathway. Moreover, -conglutin resistance to proteases at neutral pH 
values (Capraro et al., 2009)  could explain the maintenance of its activity after 48 
h of incubation, as we have observed in HepG2 cells.  
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In the present report the role of -conglutin in controlling glucose concentrations 
has been assessed using the purified protein in cell assays, however, the synergic 
effect of other protein/peptide components present in the type F sample used in “in 
vivo” experiment, cannot be excluded. In addition, the reduced increase in plasma 
glucose (-24%) and insulin (-33%) levels, recorded in rats following -conglutin 
treatment vs the values found in the pair fed animals, could be of pharmacological 
relevance. It is noteworthy, in fact that these decreases have been obtained by the 
use of a single daily administration of a purified food protein. The prerequisite for 
any biological activity is the interaction of the component under study with 
components present on plasma membrane or its direct entry into the target cells. 
This, in turn, implies that the protein can reach the district of its action in an intact 
or, at least, still active form. A number of plant and seed proteins have been found 
to be fully or partially resistant to proteolytic enzymes into the gastro-intestinal 
tract in force of their peculiar amino acid sequences and or structures (Clemente et 
al., 2000). In this respect, -conglutin was shown to undergo an ‘all or none’ 
mechanism of proteolytic degradation “in vitro”. In fact, when -conglutin native 
conformation was lost, the protein became susceptible to proteolytic enzymes; 
conversely, if the native structure was preserved, as it occurs at any pH value 
greater than 3.0, no degradation was observed (Capraro et al., 2009). In this work 
we used a different approach to get complementary information on the 
internalization and possible covalent modifications of -conglutin in HepG2 cells, 
as the basis for further studies aimed at unveiling the mechanism of action of this 
protein. Remarkably, microscopy showed that the -conglutin did get in contact 
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with the cell in the form of molecular aggregates. The spontaneous formation of 
these aggregates at neutral pH values (Capraro et al., 2010) may facilitate the 
interaction with the cell structures devoted to captation of foreign materials, such 
in the cases of albumin in astrocytes (Bento-Abreu et al., 2009) and human 1-acid 
glycoprotein (AGP) (Komori et al., 2012). Intracellular accumulation of -
conglutin is particularly evident in confocal microscopy at 6 h incubation, when 
also glucose uptake is significantly increased (64%). The 2D electrophoresis was 
carried out on HepG2 cell lysates at the same time of treatment and the lupin 
protein was detected. The position of its two subunits in the map suggested that 
the covalent integrity of the protein was preserved. However, a shift in the map of 
-conglutin related spots to more acidic pH values denoted a significant pI change 
of some polypeptides. Mass spectrometry unequivocally showed that this pI drift 
was due to multiple phosphorylation of the protein. No phosphorylation events 
have been previously described for -conglutin. 
To elucidate the cell internalization routes of -conglutin, experiments using 
specific inhibitors of endocytosis, were carried out on HepG2 cells and the uptake 
of the protein was detect by fluorescence-activated cell sorting (FACS). We have 
chosen Chlorpromazine (CPZ) and methyl-β-cyclodextrin (MβCD) to inhibit the 
clathrin-mediated endocytosis pathway (Wang et al., 1993) (Rejman et al., 2005) 
(Manunta et al., 2004; Subtil et al., 1999), filipin and genistein  (Aoki et al., 1999; 
Orlandi and Fishman, 1998; Rejman et al., 2005) to inhibit the raft/caveolae-
mediated endocytosis pathway and amiloride to inhibit macropinocytosis pathway 
(Hewlett et al., 1994). The treatment with amiloride significantly affected the 
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FITC--conglutin internalization, with an approximately 69% decrease in the 
amount of cellular uptake. The treatment with other inhibitor such as MβCD, CPZ 
and genistein showed a lower reduction in the uptake of protein (40 %, 33% and 
14% respectively). Pretreatment of the cells with filipin, had no significant effect 
on -conglutin uptake. These results suggest that in HepG2 cells -conglutin was 
internalized preferentially trough macropynocytosis pathway. 
On the other hand, the macropinocytotic pathway is one of the major physiological 
mechanism for the endocytic uptake of certain peptide sequences (Kaplan et al., 
2005; Nakase et al., 2004; Wadia et al., 2004) compared with other routes of entry 
inside the cells.  
HepG2 cells are largely used for biochemical and nutritional studies as a cell 
culture model of human hepatocytes because maintain their morphology and most 
of their function in culture (Brandon et al., 2006; Nakajima et al., 2000). Moreover, 
HepG2 cells has been used to study the hepatic glucose production and the 
modulation of the insulin pathway “in vitro”system (Lin et al., 2007; Lin and Lin, 
2008). 
To assess whether the -conglutin was involved in the activation of intracellular 
kinases like to the insulin signaling cascade on IRS-1/PI-3-kinase pathway on the  
glucose homeostasis (Saltiel and Kahn, 2001), we have processed cell protein from 
HepG2 cells. Firstly observed that incubation of cells with -conglutin alone or in 
the presence of insulin, did not induce an increase in the levels of AMPK 
phosphorylated proteins; metformin, as expect (Hawley et al., 2002) showed the 
highest levels of the pAMPK/AMPK ratio.  
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However when cell was treated with -conglutin, for 6 hours we observed a five 
fold increased in the phosphorylation of AKT and a similar rise in p-AKT value is 
present in all experimental conditions. To confirm this data, HepG2 cells were 
exposed to a selective inhibitor of AKT (LY294002); data showed that after 6 or 
24 hours of treatment, LY294002 decreased the p-AKT levels in all cells incubated 
with this inhibitor with or without presence of -conglutin or insulin alone or in 
combination. These data suggest that, this protein triggers in the PI3K/AKT 
metabolic pathways involved in the glucose homeostasis. The linkages between 
diet and health are no longer a matter of discussion. Moreover, the specific and/or 
limited effects of current drug treatments for diabetes, combined with dangerous 
effects that most of them induce, have fueled the search for alternative medicine. 
Furthermore, the specific role of many food components, their synergies and 
antagonism are still a largely unexplored area. The case of dietary 
proteins/peptides is particularly intriguing due to the dramatic changes they may 
undergo from food production to food digestion. Our findings, by showing that -
conglutin can be taken up by HepG2 cells in an intact form and is modified by 
multiple phosphorylation, open the way to more focused studies aimed to 
understand the mechanisms of action of this bioactive lupin seed protein able to 
lower glycaemia in animals and humans. 
Further studies, aimed at understanding the protein moiety of -conglutin 
responsible for the glucose-lowering effect and the molecular mechanism thereby, 
are currently being undertaken. Moreover, the hypothesis that -conglutin could 
act as an insulin-like agent should not be excluded. In conclusion, the present study 
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provides the “in vivo” and “in vitro” evidence of the involvement of -conglutin 
on cell glucose homeostasis, thus suggesting the potential use of this food protein 
in the control of glycaemia in patients with manifest or pre-clinical diabetes as well 
as for applications as functional foods and dietary supplements. 
Soybean (Glycine max) seed proteins have proved to be active in plasma 
cholesterol and triglyceride lowering activity (as demonstrated in the recent meta-
analysis involving different randomised controlled intervention studies (Anderson 
and Bush, 2011; Harland and Haffner, 2008). Controversial discussions on the key 
role played, respectively, by proteins, isoflavones, fibers and other minor 
components are still ongoing, as witnessed by another review on the topic (Dewell 
et al., 2006). But, well as the fact that each compound is probably involved in 
different pathways and mechanisms on the role of soybean proteins, in October 
1999, the U.S. Food and Drug Administration (FDA) approved a health claim that 
allowed food label claims for reduced risk of heart disease on foods that contain 
more than 6.25 g of soybean protein per serving ((FDA), 1999). In particular, a 
daily soybean protein intake of 25 g was considered beneficial, based on a number 
of previous clinical observations. 
Although the substitution of animal with plant proteins in the diet of 
hypercholesterolemic individuals is known to be associated with a significant 
cholesterol reduction since long (Hodges et al., 1967) and the identification of the 
responsible molecules, including phytoestrogens, dietary fibers, protein 
components, etc., is still matter of debate, this claim is one of the rare examples of 
an official acknowledgement of this beneficial effect of a dietary protein on health. 
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However, the amounts of soybean proteins needed to trigger the biological activity 
are extremely large from the dietetic point of view. Therefore in the last years the 
identification of the active molecule(s) has been strongly pursued as a strict 
requirement for the design of suitable intervention protocols. The first “in vivo” 
evidence of the involvement of the 7S globulin family of soybean storage proteins 
was obtained in 1992 by Lovati et al. (Lovati et al., 1992). In this study, the 
administration of 7S soybean globulin significantly reduced cholesterolemia (-
35%) vs casein fed rats. These findings were confirmed by studies on the 
stimulation of low density lipoproteins (LDL) receptors and degradation of LDL 
in cultured hepatocytes (Lovati et al., 1992). Later on, an evidence of the 
involvement of one of the 7S globulin subunits, namely the α′ subunit, was 
indirectly shown by the lack or reduced activity of a soybean cultivar naturally 
devoid of this polypeptide chain (Manzoni, 1998). Further studies (Manzoni et al., 
2003) confirmed these previous findings, by showing the up-regulation of LDL-R 
by the α′ subunit. The direct demonstration of the key role played by the α′ subunit 
in reducing plasma lipids in rats fed cholesterol-rich diet came later, thanks to the 
isolation of relatively large amounts of this subunit from the 7S globulin oligomer 
(Duranti et al., 2004). This achievement was based on the observation that the N-
terminal region of the α′ subunit, the so-called extension region, differed from the 
corresponding region of α subunit being richer in histidine residues (SwissProt 
Database accession numbers of α′ and α subunits: P11827 and P13916, 
respectively). On this basis, a preparative metal affinity chromatography column, 
was used to isolate the α′ subunit in gram amounts, making it possible to test the 
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isolated subunit in hypercholesterolemic animal models as well as in cell assays 
(Duranti et al., 2004). These results, by showing that the α′ subunit oral 
administration to rats significantly reduced plasma cholesterol and triglyceride 
levels, confirmed “in vivo” the results obtained with soybean proteins, 7S globulin 
and α′ subunit, in isolated cell systems, ruled out any isoflavone effect (Fukui et 
al., 2002) and substantiated the role of a legume dietary protein in the management 
of dislipidaemia. In addition, the up-regulation of the β-VLDL receptors in liver 
cells from hypercholesterolemic rats in response to oral treatment with this 
polypeptide was demonstrated (Duranti et al., 2004). Nonetheless, since the 
purification procedure devise is not easy to scale up, by implying a denaturation 
step to dissociate the 7S globulin oligomer, the possibility of cloning and 
expressing in proper host organisms the active subunit or a fragment thereof, 
bearing the biological activity, is currently being investigated by own group. 
Although the mentioned results represent a relevant point in the utilization of a 
dietary protein for the control of cholesterol and triglycerides hematic levels, still 
the mechanism of action of this protein is not understood. From a recent study, it 
appeared that soybean protein in the diet can also increase the size of LDL, a 
known protective effect against arterial diseases (Desroches et al., 2004). 
Moreover, the interaction of the soybean 7S globulin with thioredoxin 1 and 
cyclophilin B, two cell protein components involved in the protection from 
oxidative stress, was demonstrated (Manzoni et al., 2003). Due to the complexity 
of the metabolic and regulatory pathways involved, further research activities with 
suitable models and experimental approaches are needed to identify underlying 
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mechanism(s). All these direct evidences support the epidemiological association 
between soybean protein intake and reduced cardiovascular risk (Anderson and 
Major, 2002). Indeed, a positive effect of soybean proteins on carotids lesions in 
high fat diet fed rabbits (Castiglioni et al., 2003) and a global anti-atheromatous 
effect in mice (Adams et al., 2004) suggest a link between soybean protein 
consumption and atherosclerosis reduction.  
In this context, also the involvement of pulses other than soybean in the control of 
lipidaemic homeostasis has been considered (Dabai et al., 1996). In particular, a 
report on the reduction of plasma total and LDL-cholesterol induced by lupin 
proteins in rats on a high fat diet has appeared (Sirtori et al., 2004). In attempt to 
identifying the putative responsible molecule, γ-conglutin, a lupin protein which 
will be extensively mentioned in the following paragraph, has been put forward. 
Previously, another legume seeds, namely faba bean (Vicia faba) was proved to 
have a beneficial impact on lipid profiles. In human studies, Weck et al. (Weck et 
al., 1983) demonstrated that in hypercholesterolemic subjects, faba bean proteins 
had a cholesterol-reducing efficacy comparable to that of soybean protein. This 
effect was later confirmed on hypercholesterolemic rats by Macarulla et al. 
(Macarulla et al., 2001). 
In this study we tested different peptides from 7S soy globulin in “in vitro” and “in 
vivo” models. 
The results obtained in the present study, indicated that the compound IDN 6443 
('E), administered to rats fed  hypercholesterolemic diet, while not being able to 
reduce the levels of liver lipids, was effective in inducing a stimulation, not dose 
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dependent , in the expression of the LDL receptor. In particular, the administration 
of the reference compound (7S’-rich, IDN6442) (50 mg/kg b.w.), induced an 
increased expression of the LDL-R (+1.7 fold) compared to the values recorded in 
the control group. The compound IDN 6443 (’E), at the concentration of 25 
mg/kg b.w. resulted in a 1.8 fold increase, whereas the treatment with clofibrate 
induced a 2 fold increase in the expression of mRNA of LDL-R compared to those 
observed in the hypercholesterolemic control group. These results confirmed 
previously published data (Duranti et al., 2004) on the positive modulation of the 
LDL receptor in rats treated with the reference compound (IDN 6442).  
More studies aimed to identify the cellular molecular target in view of a possible 
association of this product with other lipid-lowering drugs, are at present object of 
evaluation. In addition, the results obtained in this experiment indicate that IDN 
6443 ('E), administered to rats fed hypercholesterolemic diet, was able to reduce, 
in a statistically significant manner, the levels of plasma lipids, both total and 
associated with the different lipoprotein classes. IDN 6443 ('E), was used at 
concentrations of 25 mg/kg b.w. (5.65 mg protein/Kg b.w.) and 50 mg/Kg b.w. 
(11.3 mg protein/kg b.w.); although the concentration of active principle is 
minimal compared to the amount of product administered, this product was 
characterized by a remarkable reduction activity of both total cholesterol (-29 and 
26%, respectively with 25 and 50 mg/kg b.w.) and  triglycerides (-13 and - 23%, 
respectively with 25 and 50 mg/kg b.w.).  The lipid-lowering effect is comparable 
to that observed in rats treated with 200 mg/kg of clofibrate, as a reference drug.   
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Alteration of cell lipid homeostasis plays a key role in the development of chronic 
diseases, such as heart failure and metabolic syndrome, which are typical of the 
affluent countries. Previous studies indicated that -conglycinin lowers plasma 
levels of cholesterol and triglycerides in humans (Kambara, 2002; Ma et al., 2013), 
as well as in animal models of human hyperlipidemia (Duranti et al., 2004; Ferreira 
Ede et al., 2011) and induces an  up-regulation of LDL high affinity receptors as 
recorded in hypercholesterolemic patients (Lovati et al., 1987) and cell cultures 
(Lovati et al., 1992; Mochizuki et al., 2009).  Although, “in vitro” and “in vivo” 
data suggest the ’ subunit as responsible of the biological effect, it is not possible 
to exclude that other subunits of -conglycinin can be involved in lipid modulation 
and/or in activities to them related. Moreover the results obtained in the present 
study pointed out that some of peptides, belonging to ’,  and  subunits of 7S 
soy globulin, when exposed to HepG2 cells displayed different effect on the 
expression of LDL-R, SREBP-2 and HMGCoA red mRNAs, as recorded by real 
time PCR. As expected simvastatin induced a marked increase of LDL-R (+1.5 
fold), SREBP-2 (+1 fold) and, a marked decrease of HMGCoA red (-60%) vs 
untreated cells. Peptide C (RKQEEDEDEEQQREE) and E (KNPQLR) tested at 1 
M concentration displayed increased expression of mRNA LDL-R (+2.3, and + 
1.9 fold), SREBP-2 (+1.8, and +3.3 fold), and a decreased expression of mRNA 
HMGCoA red (-30, and -70 %, respectively) vs values detected in untreated cells. 
This trend was similar to that observed in HepG2 cells treated with 1 M 
simvastatin. Peptide D showed similar behavior at higher concentration (10 M); 
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increased expression of mRNA LDL-R (+0.5 fold), SREBP-2 (+2 fold) vs 
untreated HepG2 cells have been detected. 
In a previous work, a marked reduction of apo B accumulation has been found in 
the media of HepG2 cells exposed both to whole 7S soy globulin and to a 
commercial isoflavone-poor soy concentrate (CroksoyR70) (Lovati et al., 2000). 
In addition, an increased up-regulation of LDL-R was detected in the same cell 
line after incubation with a synthetic peptide (MW 2271 Da) corresponding to 
positions 301-324 of ’ subunit of 7S soy globulin (Lovati et al., 2000). Moreover, 
Mochizuki et al. (Mochizuki et al., 2009) showed that short peptides (7S-peptides) 
derived from highly purified -conglycinin suppressed the secretion of 
apolipoprotein B-100 in the medium and increased the cleaved nuclear form of 
SREBP-2 in HepG2 cells. Recently, a LDL-R transcription stimulating peptide 
(FVVNATSN), deriving from 7S globulin  chain, has been identified from a 
soybean hydrolysate prepared by a protease from Bacillus amyloliquefaciens and 
then by chemical synthesis (Cho et al., 2008). In HepG2 cells in fact an increased 
LDL-R transcription (+148%) was detected at a concentration of 100 M of this 
peptide. Although the mechanism underlying the increased expression of LDL-R 
and SREBP-2 mRNAs and the reduced expression of HMGCoA reductase mRNA 
remains to be elucidated in details, it is worth to note that all peptides were potent 
inhibitors of FAS activity as reported below. 
Recently, a number of studies have suggested that FAS is a potential target for 
drug discovery. In contrast to normal tissues, high levels of FAS expression have 
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been found in many human cancers, including carcinoma of the breast, prostate, 
colon, ovary and in adipose tissue  (Berndt et al., 2007; Sheng et al., 2009). 
The discovery and development of pharmacologic FAS inhibitors are the premise 
for the treatment of cancer, diabetes, hyperlipidemia, obesity and related diseases. 
Plant-derived compounds have been discovered as potential FAS inhibitors 
(Brusselmans et al., 2005; Na et al., 2006; Rivkin et al., 2006). Previous “in vitro” 
studies have shown that soybean -conglycinin contains active peptides that 
inhibit FAS (Gonzalez de Mejia, 2009) and fatty acid biosynthesis in adipocytes 
(Martinez-Villaluenga et al., 2008). Treatment with synthetic peptides from -
conglycinin decreased lipid accumulation in the adipocytes from 12 to 27 % 
compared to negative controls (untreated cells). Previous data correlate the FAS 
inhibitory potency of soy peptides to their molecular mass. The large inhibitory 
peptide (RKQEEDEDEEQQRE) bond to thioesterase domain of human FAS 
blocking the active site, as predicted by molecular docking (Martinez-Villaluenga 
et al., 2010). The intake of 5 g of -conglycinin per day decreased visceral fat in 
humans and increased the activities of hepatic oxidation enzymes in mice and 
rats (Moriyama et al., 2004). Newly, it was shown that soybean hydrolysates play 
a role in regulating body weight (Vaughn et al., 2008) and controlling lipid 
accumulation (Martinez-Villaluenga et al., 2008). 
Recent research have suggested that oxidative stress is related to atherosclerosis 
as well as to diabetes and cancer, although the exact impact of this association has 
still to be determined  (Song et al., 2007). None of the peptides tested in present 
work which belong to ’,  and  subunit of -conglycinin showed a significant 
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anti-oxidant capacity, since the results obtained varied between 11 and 15 mol 
Trolox equivalent/mol peptide (Table 7 in results capitol). Chen et al. reported 
that soy peptides containing histidine are characterized by antioxidant properties. 
Since the peptides studied are lacking in histidine amino acid, this could justified 
their inefficacy as antioxidant compounds. Moreover, although the interaction of 
’chain, or fragment thereof, with thioredoxin 1 and cyclophilin B has been 
previously indicated (Manzoni et al., 2003) we have not information about the 
potential interaction of peptides with cell membrane components as well the 
endocytotic pathway involved. Despite the results obtained in the present study, 
Elias et al. demonstrated the improvement of the antioxidant capacity of soybean 
when protein was hydrolyzed into peptides (Elias et al., 2008). 
It is known that inflammation is part of the defense mechanism against infectious 
agents and injury. On the other hand, it is also associated to many chronic diseases 
such as cardiovascular disease, diabetes and cancer (Agarwal et al., 2009). From 
this, the reduction of expression or activity of the enzymes iNOS/COX-2 is the 
target to prevent chronic diseases related to inflammation. Nitric oxide synthases, 
(NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) 
from L-arginine.  Nitric oxide, plays an important role in the regulation of immune 
function, anti-apoptosis, and neurotransmission (Chung et al., 2001). Although it 
was demostrated (Martinez-Villaluenga et al., 2009) that protein hydrolysates from 
soybean reduced prostaglandin 2 (PGE2) production in LPS-induced 
macrophages, there is no information about the effect of purified peptides 
fromconglycinin on the iNOS and COX-2 following treatment of RAW 264.7. 
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We studied the effect of each peptide (25 M concentration) on the protein 
expression of iNOS in macrophages using Western blot. Results shows that 
expression of iNOS was differently affected by synthetic peptides, peptide A 
(SEEEEEDQ), B (QKEEEKHEWQ), and E (KNPQLR) reduced the expression of 
iNOS by 71, 75 and 44%, respectively. To evaluate the role of synthetic peptides 
in inflammation, we also measured the expression of COX-2 in LPS-stimulated 
RAW 264.7 cells. As indicated in Results section, COX-2 expression was 
markedly reduced by peptide A, B, and E by 54, 34, and 79 %, respectively. 
Peptide C (RKQEEDEDEEQQRE), and peptide D (EITPEKNPQLR) showed 
lower inhibitory activity on both inflammation markers. These data support the 
hypothesis that peptides, released by “in vitro” or “in vivo” enzymatic digestion 
from different protein components present in the soybean seed, are characterized 
by different physiological functions.  
The NPDNDE synthetic peptide corresponding to the position 314-319 of α’ chain 
7S soy globulin was tested “in vitro” and “in vivo” experiments. Results obtained 
after treatment with this peptide showed an increased mRNA expression of 
SREBP2 (+1.5; 1.2 fold), LDL-R (+2.5; 2.5 fold) and PCSK9 (+3.5; +1.5 fold) 
were detected in cells exposed to NPDNDE and simvastatin, respectively vs 
control cells. “In vivo” experiment rats fed hypercholesterolemic diet were daily 
treated by gavage with synthetic peptide NPDNDE (5 mg/Kg b.w.) for 21 days; 
the results were compared with that obtained in rats treated either with whole α’ 
(20 mg/Kg b.w.) or clofibrate (200 mg/kg b.w.), as reference drug. The oral 
administration of peptide resulted in lower plasma lipid levels (cholesterol, -37%; 
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triglycerides, -38%) vs values recorded in rats fed casein-cholesterol diet alone. 
Four-fold amounts of α’ chain reduced cholesterol and triglycerides by 37 and 
25%, respectively. Similar results were obtained in clofibrate-treated rats. 
Moreover, synthetic peptide increased the expression of mRNA of LDL-R (+ 
53%), thus restoring the receptor activity normally suppressed by the HC diet. This 
is the first “in vivo” evidence of potential activity of the NPDNDE synthetic 
peptide from α’chain 7S soy globulin on lipid homeostasis through SREBP-2 and 
PCSK9 pathways. 
The results presented in this 7S soy protein study pointed out that peptides, 
designed considering the differences among the amino acid sequences of the three 
subunits of 7S soy globulin and chemically synthesized, as well as a 
biotechnological product such as  ‘E were characterized by biological properties 
making them a suitable source of active peptides. Moreover, this study showed 
that the protein component and not any other potentially bioactive compounds, 
such as isoflavones, are responsible of the detected activities. These soy peptides 
played, in fact, a key role in the complex mechanism of cell physiology and this 
depends on the different cell line used. These molecules, following confirmation 
of their biological activity in “in vivo” models, will open to the sector of 
prevention, generating a strong impact on businesses as well as on the consumer 
health.  Moreover, the biotechnological product (’E) can effectively reduce 
cholesterolemia upregulating LDL receptor activity, a widely accepted mechanism 
of cholesterol reduction associated with the intake of vegetable proteins. The 
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growing interest in this product suggest its potential therapeutic use in 
hypercholesterolemia.  
In conclusion the results of these studies are the basis for the development of 
functional foods with beneficial effects on various diseases, including 
hyperlipidemia, diabetes, cardiovascular disease and so on, to be used alone or in 
combination with drug therapies. Moreover, the knowledge of the amino acid 
sequence responsible of the biological effect could be of help for the selection of 
soy cultivars or the production of genetically modified soybean crops rich in 
bioactive compounds.  
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